Ethylenediamine derived carboxamides of betulinic and ursolic acid as potential cytotoxic agents

Article abstract of DOI:10.3390/molecules23102558

Two easily accessible, natural occurring triterpenoids, betulinic and ursolic acid, were used as starting materials for the synthesis of novel cytotoxic agents. A set of 28 ethylenediamine-spacered carboxamides was prepared holding an additional substituent connected to the ethylenediamine group. The compounds were screened in SRB assays to evaluate their cytotoxic activity employing several human tumor cell lines. Betulinic acid-derived carboxamides 17-30 showed significantly higher cytotoxicity than their ursolic acid analogs 3-16. In particular, compounds 25 and 26 were highly cytotoxic, as indicated by EC50 values lower than 1 μM.

Full text of DOI:10.3390/molecules23102558

molecules
Article
Ethylenediamine Derived Carboxamides of Betulinic
and Ursolic Acid as Potential Cytotoxic Agents
Michael Kahnt 1 , Lucie Fischer (née Heller) 1, Ahmed Al-Harrasi 2 and René Csuk 1,
*
1
Division of Organic Chemistry, Martin-Luther-University Halle-Wittenberg, Kurt-Mothes-Str. 2, D-06120
Halle (Saale), Germany; michael.kahnt@chemie.uni-halle.de (M.K.); lucie.heller@chemie.uni-halle.de (L.F.)
Chair of Oman’s Medicinal Plants and Marine Natural Products, University of Nizwa, P.O. Box 33, Birkat
Al-Mauz, Nizwa 611, Oman; aharrasi@unizwa.edu.om
2
*
Correspondence: rene.csuk@chemie.uni-halle.de; Tel.: +49-345-55-25660
ꢀꢁꢂꢀꢃꢄꢅꢆꢇ
ꢀꢁꢂꢃꢄꢅꢆ
Received: 11 September 2018; Accepted: 3 October 2018; Published: 8 October 2018
Abstract: Two easily accessible, natural occurring triterpenoids, betulinic and ursolic acid, were used
as starting materials for the synthesis of novel cytotoxic agents. A set of 28 ethylenediamine-spacered
carboxamides was prepared holding an additional substituent connected to the ethylenediamine
group. The compounds were screened in SRB assays to evaluate their cytotoxic activity employing
several human tumor cell lines. Betulinic acid-derived carboxamides 17
–30 showed significantly
higher cytotoxicity than their ursolic acid analogs 16. In particular, compounds 25 and 26 were
3
–
highly cytotoxic, as indicated by EC50 values lower than 1 µM.
Keywords: ursolic acid; betulinic acid; cytotoxicity; triterpenoids
1. Introduction
During the last decade, significant progress has been made in the therapy of cancer, with several
major breakthroughs recorded in recent years. Two examples illustrate today’s medical advances in
fighting cancer: In August 2017, the first adoptive cell immunotherapy (chimeric antigen receptor
T-cell therapy) and the first gene therapy (tisagenlecleucel) were officially approved by the FDA [1].
However, the battle against cancer is far from being won, as the prognosis for many types of cancer
remains poor. Despite the promising therapeutic benefits of immuno- or gene therapy, chemotherapy
nonetheless remains a key means of cancer treatment. Therefore, research is and should still be focused
on the development of new bioactive drugs applicable to chemotherapy.
Many natural products show a wide range of pharmacological properties, including antiviral,
antimalarial, anti-inflammatory and antitumor activities. Thus, they are considered as ideal lead
structures for the development of new bioactive substances. Triterpenes are a class of pharmacologically
interesting natural products that also exhibit cytotoxic properties among several other biological
activities [2]. Our own work in recent years has been focused on modifications of naturally occurring
triterpenes, such as ursolic, oleanolic, glycyrrhetinic, betulinic, boswellic, platanic and maslinic acid, in
which cytotoxic agents were synthesized for their cancer-fighting properties.
The objective of this work was to improve the cytotoxic properties of the two triterpenoids,
ursolic (UA) and betulinic acid (BA), by structural modification at the C-28 carbonyl moiety. Many
modifications of UA and BA have been reported [3–5], and the cytotoxicity of these analogs was
determined. As a result, two major features seem important for obtaining compounds of high
cytotoxicity: First, an intact carbonyl group at C-28 has to be present; reduction or removal of this
moiety led to compounds of low cytotoxicity. Second, previous findings [
cytotoxicity for amino-substituted triterpenes, regardless of the position of this moiety. Hence, we
introduced an amino function into the skeleton of the triterpene, and carboxamides with -diamines,
6–11] reported an increased
α,ω
Molecules 2018, 23, 2558; doi:10.3390/molecules23102558
www.mdpi.com/journal/molecules

Molecules 2018, 23, 2558
2 of 19
such as ethylenediamine, were prepared. Furthermore, ethylenediamine-spacered carboxamides of
oleanolic (OA) or platanic acid (PA) have previously been shown to be highly cytotoxic for human
tumor cell lines [10,12]. Ursolic and betulinic acid were chosen as starting compounds: they are easily
accessible and structurally related to OA and PA, respectively (Figure 1).
Figure 1. Structures of oleanolic (OA), ursolic (UA), platanic (PA) and betulinic acid (BA).
2. Results and Discussion
2.1. Chemistry
Acetylation of betulinic (BA) and ursolic acid (UA) yielded acetates
1 and 2. The carboxamides
3
–
30 were prepared in two steps (Scheme 1). Thus, the acetates and were treated with oxalyl chloride
1
2
in dry dichloromethane in the presence of a catalytic amount of N,N-dimethylformamide to yield the
corresponding acyl chlorides, which were used without further purification. Subsequent treatment of
the crude acyl chlorides with various amines in dry dichloromethane provided carboxamides 3–9 and
17–23. Their deacetylation yielded compounds 10–16 and 24–30, respectively.
◦
Scheme 1. Synthesis of ursolic and betulinic carboxamides
3
–
30: (
a
) Ac2O, NEt3, DCM, 25 C, 2 days,
yielding
1
(96%) and
2
(93%); (
b
) oxalyl chloride, DCM, DMF, 0–25 ◦C, 1 h, then amine, 25 ◦C, 2 h,
◦
yielding 3–9 and 17–23; (c) MeOH/KOH, 25 C, 2–3 days, yielding 10–16 and 24–30.

Molecules 2018, 23, 2558
3 of 19
2.2. Biology
The cytotoxicity of ursolic and betulinic carboxamides
3–
30 was determined in sulforhodamine B
(SRB) assays [13]. The results of this screening are compiled in Table 1.
Table 1. Cytotoxicity of compounds 3–30, betulinic acid (BA), ursolic acid (UA), and doxorubicin
hydrochloride (DRC): EC50 values from SRB assays after 96 h of treatment are given in µM (n.d. not
detected); the values are averaged from three independent experiments each performed in triplicate;
confidence interval CI = 95%.
518A2
A2780
HT29
MCF-7
8505C
NIH 3T3
BA
UA
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
DRC
9.4 ± 0.70
14.7 ± 0.1
2.7 ± 0.10
5.3 ± 0.40
4.5 ± 0.20
12.2 ± 0.30
3.2 ± 0.10
2.7 ± 0.10
3.5 ± 0.60
3.7 ± 0.50
6.6 ± 0.30
5.5 ± 0.10
12.6 ± 0.20
7.0 ± 0.40
9.3 ± 0.10
9.9 ± 0.20
1.6 ± 0.10
1.3 ± 0.10
1.5 ± 0.10
3.1 ± 0.30
2.5 ± 0.70
1.0 ± 0.03
1.9 ± 0.01
0.4 ± 0.01
0.3 ± 0.16
0.4 ± 0.06
0.5 ± 0.10
0.9 ± 0.21
0.4 ± 0.06
0.5 ± 0.04
0.2 ± 0.05
8.8 ± 0.90
11.7 ± 0.6
2.3 ± 0.10
3.6 ± 0.40
3.1 ± 0.20
6.5 ± 0.50
2.4 ±0.10
2.6 ± 0.10
3.4 ± 0.50
3.3 ± 0.10
4.3 ± 0.50
3.3 ± 0.30
7.6 ± 0.60
4.9 ± 0.40
5.4 ± 1.40
6.5 ± 1.40
1.4 ± 0.20
1.1 ± 0.05
1.4 ± 0.09
1.6 ± 0.20
1.5 ± 0.06
1.1 ± 0.03
1.5 ± 0.10
0.4 ± 0.03
0.2 ± 0.01
0.3 ± 0.10
0.4 ± 0.10
0.8 ± 0.04
0.6 ± 0.10
0.5 ± 0.04
0.01 ± 0.01
14.4 ± 2.3
10.6 ± 0.7
1.8 ± 0.10
3.4 ± 0.30
2.1 ± 0.20
4.2 ± 0.50
1.8 ± 0.20
1.7 ± 0.10
1.6 ± 0.10
2.0 ± 0.10
3.0 ± 0.20
2.6 ± 0.30
8.4 ± 0.70
2.8 ± 0.40
2.1 ± 0.30
3.1 ± 0.30
1.0 ± 0.30
0.3 ± 0.02
0.5 ± 0.08
0.8 ± 0.10
0.6 ± 0.30
0.6 ± 0.05
0.4 ± 0.10
0.4 ± 0.02
0.3 ± 0.05
0.4 ± 0.02
0.4 ± 0.03
0.8 ± 0.18
0.4 ± 0.10
0.5 ± 0.07
0.9 ± 0.2
10.2 ± 1.2
12.7 ± 0.1
2.0 ± 0.10
3.3 ± 0.70
2.9 ± 0.70
6.0 ± 0.90
2.7 ± 0.30
1.7 ± 0.10
2.3 ± 0.40
3.2 ± 0.30
4.2 ± 0.90
3.5 ± 1.00
11.1 ± 1.40
4.4 ± 0.10
5.5 ± 1.10
6.3 ± 0.60
1.3 ± 0.06
1.0 ± 0.30
1.2 ± 0.20
1.5 ± 0.50
1.9 ± 0.10
0.8 ± 0.04
1.4 ± 0.20
0.4 ± 0.02
0.3 ± 0.07
0.2 ± 0.05
0.4 ± 0.01
0.3 ± 0.02
0.6 ± 0.10
0.4 ± 0.20
1.1 ± 0.3
n.d.
13.1 ± 1.1
18.7 ± 1.6
2.6 ± 0.30
3.7 ± 0.20
3.3 ± 0.30
7.2 ± 1.20
2.2 ± 0.10
1.3 ± 0.20
3.1 ± 0.40
3.9 ± 0.10
6.7 ± 1.30
6.2 ± 0.40
3.5 ± 0.60
6.6 ± 0.60
5.6 ± 0.30
7.5 ± 0.80
1.4 ± 0.10
1.0 ± 0.40
1.2 ± 0.07
1.2 ± 0.20
1.0 ± 0.05
0.6 ± 0.04
1.0 ± 0.10
0.4 ± 0.02
0.3 ± 0.09
0.4 ± 0.02
0.4 ± 0.01
0.8 ± 0.22
0.5 ± 0.10
0.4 ± 0.07
0.06 ± 0.03
13.5 ± 1.5
4.1 ± 0.40
8.3 ± 0.70
4.3 ± 0.20
15.5 ± 2.7
5.4 ± 0.40
3.2 ± 0.01
5.8 ± 0.40
3.7 ± 0.40
7.3 ± 0.20
5.7 ± 0.20
11.1 ± 0.30
7.8 ± 0.50
10.8 ± 1.20
10.6 ± 1.10
2.5 ± 0.03
1.4 ± 0.15
1.6 ± 0.09
3.0 ± 0.36
1.1 ± 0.09
1.4 ± 0.05
2.2 ± 0.81
0.4 ± 0.07
0.4 ± 0.04
0.5 ± 0.06
0.8 ± 0.09
0.85 ± 0.17
0.8 ± 0.26
0.2 ± 0.01
1.1 ± 0.4
Ursolic acid-derived amides
M. For HT29 tumor cells and compound
0.10 M was observed. Variation of the alkyl substituents at the terminal amino group of
or 10 13) did not influence the cytotoxic properties
and 13: their EC50 values are significantly higher as
3–16 were found cytotoxic; their EC50 values were between 15
µM
and 1
of 1.6
µ
9
, the most potent ursolic acid derivative, an EC50 value
µ
M
±
µ
the ethylenediamine spacer (as in compounds
3–
6
–
at all. Exceptions, however, are the compounds
6
compared to other ursolic carboxamides. For ethylenediamine-spacered carboxamides, substitution at
position 3 with an acetyl group did not affect EC50 values. Close inspection of the results, however,
revealed a small influence of the acetyl moiety at position C-3. Thus, 3-O-acetyl-derivatives
significantly lower EC50 values than their deacetylated analogues 13–16 (Figure 2).
6–9 show
Betulinic acid-derived carboxamides 17
acid derived analogs ( 16), showing EC50 values ranging between 5
particularly evident for compounds 13 and 27 or 16 and 30 (Figure 2). The most active compounds,
however, 25 and 26, showed EC50 values of 0.2 0.01 M (25) and 0.3 0.1 M (26) for
A2780 tumor cells. Compared to the known chemotherapeutic agent doxorubicin hydrochloride (DRC
–
30 were more cytotoxic than their corresponding ursolic
3–
µ
M and 0.2 M. This is
µ
µM
±
µ
µM
±
µ
,

Molecules 2018, 23, 2558
4 of 19
EC50 = 0.01
±
0.01
µ
M), the activities of 25 and 26 are reduced by factors of 20 and 30, respectively.
With respect to the MCF-7 human tumor cell line, however, 25 (EC50 = 0.3
(EC50 = 0.2 0.05 M) are even more cytotoxic than the reference compound (DRC, EC50 = 1.1
0.3 M). Calculations using the SwissTargetPrediction suggest that 25 and 26 may be possible inhibitors
µM
±
0.07 µM) and 26
µ
M
±
µ
±
µ
of tyrosine phosphates [14].
Moreover, substituents exerted similar influence for betulinic acid as well as for ursolic
acid-derived carboxamides. The presence of extra substituents at the ethylenediamine spacer also
had no influence onto the cytotoxicity of the compounds. However, differences between 3-O-acetyl-
derivatives 17–23 and deacetylated analogs 24–30 were observed. Interestingly, a different trend
becomes visible for most of the compounds as compared to the carboxamides from ursolic acid.
Thereby, compounds holding an acetyl moiety at position 3 are significantly less cytotoxic than the
corresponding 3-hydroxy-derivatives. This trend is illustrated in Figure 2 for compounds 20 and 27
and 23 and 30, respectively.
Figure 2. Comparison of EC50 values of selected ursolic and betulinic carboxamides for MCF-7 tumor cells.
In addition to EC50 values, the selectivity (which is defined as selectivity index (SI); SI = EC50 (NIH
3T3)/EC50 (tumor cell line)) is an important parameter to characterize a compound’s cytotoxic activity.
Therefore, the SI of each substance with respect to the individual tumor cell lines was determined
(Table 2). Unfortunately, for most of the compounds, selectivity towards cancerous cells is quite poor, as
indicated by SI factors close to 1. Some compounds even showed reverse selectivity behavior (SI < 1).
Selectivity trends are best seen by close inspection of the SI factors for HT29 tumor cells. For ursolic
acid derivatives
The most selective ursolic acid derivative is compound 15, with an SI of 2.67 for HT29 cells. Its acetylated
analogue only shows an SI of 0.76 for the same cancerous cell line. Similar to the trends observed
for EC50 values, a different trend with regard to selectivity becomes visible for betulinic carboxamides
17 30 as compared to ursolic analogs. Removal of the 3-O-acetyl moiety seems to result in a loss of
3–16, selectivity towards HT29 cells is increased by removing the 3-O-acetyl moiety.
8
–
selectivity. The highest selectivity was observed for compound 18 with SI = 3.33 (NIH 3T3/HT29).
Hence it is three times more cytotoxic towards HT29 tumor cells than towards nonmalignant mouse
fibroblasts. Thus, its selectivity is only slightly smaller than that of the known chemotherapeutic agent
doxorubicin hydrochloride (DRC), which shows an SI of 6 towards A2780 tumor cells. Interestingly,

Molecules 2018, 23, 2558
5 of 19
compound 25, the deacetylated analog of 18, shows no selectivity for HT29 tumor cells at all (SI = 1.00).
For the two most active compounds 25 and 26, decreased selectivity was observed. SI factors are close
to 1 for most of the cancerous cell lines. However, both compounds are slightly selective towards A2780
tumor cells (25: SI = 1.5; 26: SI = 1.33) and in case of compound 26, selectivity for MCF-7 tumor cells
was also observed (SI = 2.00).
Table 2. Selectivity of compounds
3–30, betulinic acid (BA), ursolic acid (UA) and doxorubicin
hydrochloride (DRC): Selectivity index (SI) is defined as: SI = EC50 (NIH 3T3)/EC50 (tumor cell line).
(518A2)
A2780
HT29
MCF-7
8505C
BA
UA
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
DRC
1.39
1.27
0.96
0.70
0.73
0.59
0.69
0.48
0.89
1.05
1.02
1.13
0.28
0.94
0.60
0.76
0.88
0.77
0.80
0.39
0.40
0.60
0.53
1.00
1.00
1.00
0.80
0.89
1.25
0.80
0.30
1.49
1.59
1.13
1.03
1.06
1.11
0.92
0.50
0.91
1.18
1.56
1.88
0.46
1.35
1.04
1.15
1.00
0.91
0.86
0.75
0.67
0.55
0.67
1.00
1.50
1.33
1.00
1.00
0.83
0.80
6.00
0.91
1.76
1.44
1.09
1.57
1.71
1.22
0.76
1.93
1.95
2.23
2.38
0.42
2.36
2.67
2.42
1.40
3.33
2.40
1.50
1.67
1.00
2.50
1.00
1.00
1.00
1.00
1.00
1.25
0.80
0.07
1.28
1.47
1.30
1.12
1.14
1.20
0.81
0.76
1.35
1.22
1.60
1.77
0.32
1.50
1.02
1.19
1.08
1.00
1.00
0.80
0.53
0.75
0.71
1.00
1.00
2.00
1.00
2.67
0.83
1.00
0.05
-
1.39
0.63
0.45
0.77
0.46
0.41
0.41
0.53
1.05
0.92
1.09
0.32
0.85
0.52
0.71
0.56
0.71
0.75
0.40
0.91
0.43
0.45
1.00
0.75
0.80
0.50
0.94
0.63
2.00
0.05
Extended biological investigations were performed for compounds 25 and 26 using dye exclusion
acridine orange (AO)/propidium iodide (PI) assays by treating MCF-7 or A2780 tumor cells with 25
and 26, respectively for 24 h (Figure 3). Fluorescence microscopic images of MCF-7 cells treated with
compound 25 showed, in addition to many vital cells, both apoptotic (membrane blebbing, marked by
white arrows in Figure 3) and necrotic cells (red staining). After treatment of MCF-7 cells with 26, intact
cell membranes (green staining) were observed. Close inspection revealed the presence of protrusions
in the plasma membrane (blebbing) of some cells, which can be considered a feature of apoptosis.
A2780 human tumor cells treated with 25 (1 µM) or 26 (1 µM) showed both green colored cells as well
as late-stage apoptotic cells recognizable by orange stained nuclei. For both compounds, membrane
blebbing of some cells could also be observed. These observations can be regarded as indications of
apoptosis. This parallels previous findings for related oleanolic [12] and platanic carboxamides [10],
whose cytotoxicity mechanisms were investigated using Annexin V-FITC/PI assays and cell cycle
evaluation, and which showed them to trigger cell death by apoptosis.

Molecules 2018, 23, 2558
6 of 19
Figure 3. Fluorescence microscopic images: (
A
) treatment of MCF-7 cells with 25 (1
µM) and 26
(0.75 M) for 24 h; ( ) treatment of A2780 cells with 25 (1
µ
B
µ
M) and 26 (1 M) for 24 h; scale bar = 10 µ
µ
m,
AO and PI were used.
3. Materials and Methods
3.1. General
NMR spectra were recorded using the Varian spectrometers Gemini 2000 or Unity 500 (δ given
in ppm, J in Hz; typical experiments: APT, H-H-COSY, HMBC, HSQC, NOESY), MS spectra were
recorded on a Finnigan MAT LCQ 7000 (electrospray, voltage 4.1 kV, sheath gas nitrogen) instrument.
The optical rotations were measured on a Perkin-Elmer polarimeter at 20 ◦C; TLC was performed on
silica gel (Merck 5554, detection with cerium molybdate reagent); melting points are uncorrected (Leica
hot stage microscope), and elemental analyses were performed on a Foss-Heraeus Vario EL (CHNS)
unit. IR spectra were recorded on a Perkin Elmer FT-IR spectrometer Spectrum 1000. The solvents
were dried according to usual procedures. The purity of the compounds was determined by HPLC
and found to be >96%. Ursolic (UA) and betulinic acids (BA) were obtained from betulinines (Strˇíbrná
Skalice, Czech Republic) in bulk quantities. Fluorescence microscopic images were recorded on an
Axioskop 20 with an AxioCam MR3 (Carl Zeiss AG, Oberkochen, Germany).
3.2. Biology
3.2.1. Cell Lines and Culture Conditions
The cell lines used were human cancer cell lines: 518A2 (melanoma), A2780 (ovarian carcinoma),
HT29 (colon adenocarcinoma), MCF-7 (breast adenocarcinoma), 8505C (thyroid carcinoma) and
non-malignant mouse fibroblasts NIH 3T3. Cultures were maintained as monolayers in RPMI 1640
medium with L-glutamine (Capricorn Scientific GmbH, Ebsdorfergrund, Germany) supplemented
with 10% heat inactivated fetal bovineserum (Sigma-Aldrich Chemie GmbH, Steinheim, Germany)
and penicillin/streptomycin (Capricorn Scientific GmbH, Ebsdorfergrund, Germany) at 37 ◦C in a
humidified atmosphere with 5% CO2.
3.2.2. Cytotoxic Assay (SRB)
The cytotoxicity of the compounds was evaluated using the sulforhodamine-B (Kiton-Red S,
ABCR) micro culture colorimetric assay. Cells were seeded into 96-well plates on day 0 at appropriate
cell densities to prevent confluence of the cells during the period of experiment. After 24 h, the
cells were treated with 6 different concentrations (1, 3, 7, 12, 20 and 30 µM) minimum. The final

Molecules 2018, 23, 2558
7 of 19
concentration of DMSO/DMF never exceeded 0.5%, which was non-toxic to the cells. After a 96 h
treatment, the supernatant medium from the 96-well◦plates was discarded, the cells were fixed with
10% trichloroacetic acid (TCA) and allowed to rest at 4 C. After 24 h fixation, the cells were washed in a
strip washer and dyed with SRB solution (100
the plates were washed four times with 1% acetic acid to remove the excess of the dye and allowed
to air-dry overnight. Tris base solution (200 L, 10 mM) was added to each well and absorbance was
measured at = 570 nm using a 96-well plate reader (Tecan Spectra, Crailsheim, Germany). The EC50
µL, 0.4% in 1% acetic acid) for about 20 min. After dying,
µ
λ
values were averaged from three independent experiments performed each in triplicate calculated
from semi logarithmic dose response curves applying a non-linear 4P Hills-slope equation (GraphPad
Prism5; variables top and bottom were set to 100 and 0, respectively).
3.2.3. AO/PI Dye Exclusion Test
Morphological characteristics of cell death were analyzed employing an AO/PI assay using human
cancer cell lines A2780 and MCF-7. Approximately 8
×
105 cells were seeded in cell culture flasks
(25 cm2), and the cells were allowed to grow for 24 h. After removing the used medium, fresh medium
was reloaded (or a blank new medium was used as a control). After 24 h, the content of the flask was
◦
collected and centrifuged (1200 rpm, 4 C), and the pellet was gently suspended in phosphate-buffered
saline (PBS (w/w), 1 mL) and centrifuged again. The PBS was removed, and the pellet gently suspended
in PBS (50 µL) again. The analysis of the cells was performed using a fluorescence microscope after
having mixed the cell suspension (10 µL) with a solution of AO/PI (1 µg/mL, 10 µL).
4. Experimental
4.1. General Procedure A for the Acetylation of Triterpenoic Acids (1–2)
To a solution of UA or BA (5 g, 11 mmol) in dry DCM (150 mL) was added triethylamine (4.6 mL,
33 mmol), acetic anhydride (3.1 mL, 33 mmol) and DMAP (cat.). After stirring for 2 days at 25 ◦C, a
saturated solution of NH3 in MeOH was added (3 mL), and the mixture was stirred for another 30 min.
Dilution with DCM and subsequent aqueous work-up provided crude 3-O-acetyl-UA or 3-O-acetyl-BA.
Recrystallization from EtOH yielded pure acetates 1 (5.3 g, 96%) and 2 (5.1 g, 93%) both as colorless
solids, whose analytical and spectroscopic data were in full agreement with data from the literature.
4.2. General Procedure B for the Synthesis of Triterpenoic Amides (3–9, 17–23)
◦
Compounds
1
or
2
(0.8 mmol) were each dissolved in dry DCM (15 mL), cooled to 0 C, and
oxalyl chloride (3.2 mmol) and dry DMF (3 drops) were added. After warming to 25 ◦C, the mixture
was stirred for 1 h. The solvent was removed under reduced pressure, re-evaporated with dry THF
(
4 × 15 mL), and the residue was immediately resolved in dry DCM (10 mL). This mixture was then
added dropwise to a solution of the amine (2.4 mmol) in dry DCM (5 mL) and stirred at 25 ◦C for 2 h.
After usual aqueous work-up, the solvent was removed under reduced pressure, and the crude product
was subjected to column chromatography (silica gel, chloroform/methanol mixtures). Compounds
3–9 and 17–23 were each obtained as colorless solids.
4.3. General Procedure C for Deacetylation of Triterpenoic Amides (10–16, 24–30)
To a solution of acetylated amides
3
–
9
or 17
–
23 (0.33 mmol) in methanol (10 mL) was added a
◦
solution of potassium hydroxide (1.65 mmol) in methanol (2 mL). The mixture was stirred at 25 C for
2 or 3 days. After completion of the reaction (as indicated by TLC), aq. HCl was added until pH = 7.
After usual work-up, the solvent was removed under reduced pressure, and the residue was subjected
to column chromatography (silica gel, chloroform/methanol mixtures) yielding compounds 10
and 24–30 each as colorless solids.
–16

Molecules 2018, 23, 2558
8 of 19
(3
β
)-3-Acetyloxy-urs-12-en-28-oic acid (
1
). Compound
1
was prepared according to general procedure A
from ursolic acid. Yield: 96%; m.p. 287–290 ◦C (lit.: 289–290 ◦C [15]).
(3
β)-3-Acetyloxy-lup-20(29)en-28-oic acid (2). Compound 2 was prepared according to general procedure
A from betulinic acid. Yield: 93%; m.p. 281–284 ◦C (lit.: 280-282 ◦C [16]).
(3 )-N-(2-Aminoethyl)-3-acetyloxy-urs-12-en-28-amide ( ). Compound was prepared from
to general procedure B using ethylenediamine. Column chromatography (SiO2, CHCl3/MeOH 9:1)
gave
(yield: 80%); m.p. 202–205 ◦C (lit.: 140–142 ◦C [17]); [ ]D = +39.4◦ (c 0.355, CHCl3); Rf = 0.48
(CHCl3/MeOH 9:1); IR (KBr): = 3413br s, 2948s, 1735s, 1633s, 1526s, 1456s, 1370s, 1247s, 1174w, 1147w,
1092w, 1028s, 1006m, 986m, 755m cm−1; 1H-NMR (500 MHz, CDCl3):
= 6.88 (t, J = 5.3 Hz, 1H, NH),
β
3
3
1 according
3
δ
ν
δ
5.34 (t, J = 3.3 Hz, 1H, 12-H), 4.49 (dd, J = 10.0, 5.9 Hz, 1H, 3-H), 3.62–3.54 (m, 1H, 31-Ha), 3.38–3.30
(m, 1H, 31-Hb), 3.13–3.01 (m, 2H, 32-Ha, 32-Hb), 2.09–2.04 (m, 1H, 18-H), 2.04 (s, 3H, Ac), 2.03–1.87
(m, 3H, 16-Ha, 11-Ha, 11-Hb), 1.82–1.22 (m, 15H, 22-Ha, 16-Hb, 1-Ha, 15-Ha, 2-Ha, 2-Hb, 9-H, 22-Hb,
6-Ha, 21-Ha, 7-Ha, 19-H, 6-Hb, 7-Hb, 21-Hb), 1.08 (s, 3H, 27-H), 1.07–0.95 (m, 3H, 1-Hb, 15-Hb, 20-H),
0.96–0.92 (m, 4H, 25-H, 20-H), 0.89–0.85 (m, 6H, 23-H, 29-H), 0.85 (s, 3H, 24-H), 0.84–0.80 (m, 1H, 5-H),
0.74 (s, 3H, 26-H) ppm; 13C-NMR (126 MHz, CDCl3):
δ = 180.2 (C-28), 171.1 (Ac), 139.3 (C-13), 126.0
(C-12), 81.0 (C-3), 55.4 (C-5), 53.1 (C-18), 47.9 (C-17), 47.6 (C-9), 42.4 (C-14), 40.6 (C-32), 39.8 (C-19),
39.7 (C-8), 39.0 (C-20), 38.7 (C-31), 38.5 (C-1), 37.8 (C-4), 37.4 (C-22), 37.0 (C-10), 32.8 (C-7), 31.0 (C-21),
28.2 (C-23), 28.0 (C-15), 24.8 (C-16), 23.7 (C-2), 23.5 (C-11), 23.5 (C-27), 21.4 (Ac), 21.3 (C-30), 18.3 (C-6),
17.4 (C-29), 17.2 (C-26), 16.9 (C-24), 15.7 (C-25) ppm; MS (ESI, MeOH): m/z = 541 (100 %, [M + H]+);
analysis calcd for C34H56N2O3 (540.83): C 75.51, H 10.44, N 5.18; found: C 75.32, H 10.61, N 5.01.
(3
according to general procedure B using N,N-dimethylethylenediamine. Column chromatography
(SiO2, CHCl3/MeOH 95:5) gave
(yield: 88%); m.p. 121–124 ◦C; [ D = +44.9◦ (c 0.300, CHCl3); Rf =
0.49 (CHCl3/MeOH 9:1); IR (KBr): = 3422br m, 2937m, 1734m, 1636m, 1522w, 1457m, 1384s, 1247m,
1028m cm−1; 1H-NMR (500 MHz, CDCl3):
= 6.68 (t, J = 5.0 Hz, 1H, NH), 5.33 (t, J = 3.4 Hz, 1H, 12-H),
β)-N-[2-(Dimethylamino)ethyl]-3-acetyloxy-urs-12-en-28-amide (4). Compound 4 was prepared from
1
4
α]
ν
δ
4.48 (dd, J = 10.5, 5.6 Hz, 1H, 3-H), 3.62–3.52 (m, 1H, 31-Ha), 3.29–3.21 (m, 1H, 31-Hb), 2.83 (t, J = 5.3
Hz, 2H, 32-H), 2.58 (s, 6H, 33-H, 330-H), 2.03 (s, 3H, Ac), 2.02–1.86 (m, 4H, 16-Ha, 18-H, 11-Ha, 11-Hb),
1.83–1.76 (m, 1H, 22-Ha), 1.73–1.67 (m, 1H, 16-Hb), 1.67–1.57 (m, 4H, 1-Ha, 15-Ha, 2-Ha, 2-Hb), 1.57–1.26
(m, 9H, 9-H, 6-Ha, 7-Ha, 21-Ha, 22-Hb, 19-H, 6-Hb, 21-Hb, 7-Hb), 1.07 (s, 3H, 27-H), 1.06–0.94 (m, 3H,
1-Hb, 15-Hb, 20-H), 0.93 (d, J = 6.1 Hz, 3H, 30-H), 0.93 (s, 3H, 25-H), 0.87 (d, J = 6.5 Hz, 3H, 29-H), 0.85
(s, 3H, 23-H), 0.84 (s, 3H, 24-H), 0.83–0.80 (m, 1H, 5-H), 0.75 (s, 3H, 26-H) ppm; 13C-NMR (126 MHz,
CDCl3):
δ = 179.1 (C-28), 171.1 (Ac), 139.2 (C-13), 126.0 (C-12), 81.0 (C-3), 57.7 (C-32), 55.4 (C-5), 53.4
(C-18), 47.9 (C-17), 47.6 (C-9), 44.6 (C-33, C-330), 42.4 (C-14), 39.8 (C-19), 39.7 (C-8), 39.0 (C-20), 38.4
(C-1), 37.8 (C-4), 37.4 (C-22), 37.0 (C-10), 35.9 (C-31), 32.8 (C-7), 31.0 (C-21), 28.2 (C-23), 28.0 (C-15), 24.8
(C-16), 23.7 (C-2), 23.5 (C-11), 23.4 (C-27), 21.4 (Ac), 21.3 (C-30), 18.3 (C-6), 17.3 (C-29), 17.1 (C-26), 16.9
(C-24), 15.7 (C-25) ppm; MS (ESI, MeOH): m/z = 569 (100%, [M + H]+); analysis calcd for C36H60N2O3
(568.89): C 76.01, H 10.63, N 4.92; found: C 75.87, H 10.84, N 4.69.
(3
according to general procedure B using 1-(2-aminoethyl)-pyrrolidine. Column chromatography (SiO2,
CHCl3/MeOH 95:5) gave
(yield: 92%). m.p. 156–159 ◦C; [ ]D = +45.9◦ (c 0.355, CHCl3); Rf = 0.44
(CHCl3/MeOH 9:1); IR (KBr): = 3404br s, 2948s, 1734s, 1651s, 1526s, 1456s, 1371s, 1246s, 1146w,
1091m, 1027s, 1006m, 985m, 753m cm−1; 1H-NMR (500 MHz, CDCl3):
= 6.90 (dd, J = 11.5, 5.6 Hz, 1H,
β)-N-(2-Pyrrolidin-1-ylethyl)-3-acetyloxy-urs-12-en-28-amide (5). Compound 5 was prepared from 1
5
α
ν
δ
NH), 5.36 (dd, J = 7.1, 3.6 Hz, 1H, 12-H), 4.47 (dd, J = 10.5, 5.3 Hz, 1H, 3-H), 3.89–3.82 (m, 1H, 31-Ha),
3.82–3.730(m, 2H, 33-Ha, 330-Ha) 3.41–3.32 (m, 1H, 31-Hb), 3.30–3.21 (m, 2H, 32-H), 2.93–2.83 (m, 2H,
0
33-Hb, 33 -Hb), 2.23–2.06 (m, 4H, 34-H, 34 -H), 2.02 (s, 3H, Ac), 2.01–1.95 (m, 2H, 16-Ha, 18-H), 1.95–1.90
(m, 2H, 11-Ha, 11-Hb), 1.76–1.56 (m, 6H, 22-Ha, 16-Hb, 1-Ha, 15-Ha, 2-Ha, 2-Hb), 1.55–1.41 (m, 5H, 9-H,
6-Ha, 22-Hb, 7-Ha, 21-Ha), 1.41–1.21 (m, 4H, 19-H, 6-Hb, 7-Hb, 21-Hb), 1.06 (s, 3H, 27-H), 1.10–0.94 (m,
3H, 1-Hb, 15-Hb, 20-H), 0.92 (s, 3H, 25-H), 0.91 (d, J = 6.1 Hz, 3H, 30-H), 0.86 (d, J = 6.5 Hz, 3H, 29-H),

Molecules 2018, 23, 2558
9 of 19
0.84 (s, 3H, 23-H), 0.83 (s, 3H, 24-H), 0.82–0.78 (m, 1H, 5-H), 0.71 (s, 3H, 26-H) ppm; 13C-NMR (126
MHz, CDCl3):
δ
0
= 179.8 (C-28), 171.1 (Ac), 138.9 (C-13), 126.0 (C-12), 80.9 (C-3), 55.3 (C-5), 55.0 (C-32),
54.8 (C-33, C-33 ), 52.9 (C-18), 47.9 (C-17), 47.5 (C-9), 42.3 (C-14), 39.7 (C-19), 39.7 (C-8), 38.8 (C-20), 38.4
(C-1), 37.8 (C-4), 37.4 (C-22), 37.0 (C-10), 36.2 (C-31), 32.8 (C-7), 30.9 (C-21), 28.2 (C-23), 27.9 (C-15),
24.7 (C-16), 23.6 (C-2), 23.5 (C-27), 23.4 (C-11), 23.3 (C-34, C-340), 21.4 (Ac), 21.3 (C-30), 18.3 (C-6), 17.2
(C-29), 17.1 (C-26), 16.8 (C-24), 15.6 (C-25) ppm; MS (ESI, MeOH): m/z = 595 (100%, [M + H]+); analysis
calcd for C38H62N2O3 (594.93): C 76.72, H 10.50, N 4.71; found: C 76.60, H 10.72, N 4.59.
(3
according to general procedure B using 1-(2-aminoethyl)-piperidine. Column chromatography (SiO2,
CHCl3/MeOH 95:5) gave
(yield: 83%); m.p. 124–127 ◦C; [ ]D = +34.6◦ (c 0.365, CHCl3); Rf = 0.26
(CHCl3/MeOH 95:5); IR (KBr): = 3424br s, 2936s, 2872m, 2854m, 1736s, 1638s, 1508m, 1456m, 1370m,
1246s, 1154w, 1128w, 1092w, 1028m cm−1; 1H-NMR (400 MHz, CDCl3):
= 6.56–6.51 (m, 1H, NH), 5.30
β)-N-(2-Piperidin-1-ylethyl)-3-acetyloxy-urs-12-en-28-amide (6). Compound 6 was prepared from 1
6
α
ν
δ
(t, J = 3.6 Hz, 1H, 12-H), 4.49 (dd, J = 10.04, 5.8 Hz, 1H, 3-H), 3.41–3.29 (m, 1H, 31-Ha), 3.24–3.12 (m, 1H,
31-Hb), 2.49–2.27 (m, 6H, 32-H, 33-H, 33 -H), 2.03 (s, 3H, Ac), 2.01–1.80 (m, 5H, 16-Ha, 11-Ha, 11-Hb, 18,
22-Ha), 1.78–1.22 (m, 20H, 16-Hb, 15-Ha, 1-Ha, 2-Ha, 2-Hb, 34-H, 340-H, 9-H, 6-Ha, 21-Ha, 7-Ha, 35-H,
22-Hb, 19-H, 6-Hb, 21-Hb, 7-Hb), 1.08 (s, 3H, 27-H), 1.14–0.96 (m, 3H, 1-Hb, 15-Hb, 20-H), 0.95–0.93
(m, 3H, 30-H), 0.93 (s, 3H, 25-H), 0.88 (d, J = 6.5 Hz, 3H, 29-H), 0.86 (s, 3H, 23-H), 0.85 (s, 3H, 24-H),
0.84–0.79 (m, 1H, 5-H), 0.77 (s, 3H, 26-H) ppm; 13C-NMR (101 MHz, CDCl3):
δ = 178.0 (C-28), 171.1
(Ac), 139.5 (C-13), 125.6 (C-12), 81.0 (C-3), 57.2 (C-32), 55.4 (C-5), 54.5 (C-33, C-330), 54.0 (C-18), 47.9
(C-17), 47.6 (C-9), 42.5 (C-14), 39.9 (C-19), 39.7 (C-8), 39.2 (C-20), 38.4 (C-1), 37.8 (C-4), 37.5 (C-22), 37.0
(C-10), 36.0 (C-31), 32.9 (C-7), 31.1 (C-21), 28.2 (C-23), 28.0 (C-15), 26.2 (C-34, C-340), 24.9 (C-16), 24.5
(C-35), 23.7 (C-2), 23.5 (C-11), 23.4 (C-27), 21.4 (Ac), 21.4 (C-30), 18.3 (C-6), 17.5 (C-29), 17.1 (C-26), 16.9
(C-24), 15.7 (C-25) ppm; MS (ESI, MeOH): m/z = 609 (100%, [M + H]+); analysis calcd for C39H64N2O3
(608.95): C 76.92, H 10.59, N 4.60; found: C 76.77, H 10.79, N 4.41.
(3
according to general procedure B using 1-(2-aminoethyl)-piperazine. Column chromatography (SiO2,
CHCl3/MeOH 9:1) gave
(yield: 82%); m.p. 145–147 ◦C (lit.: 147–150 ◦C [18]); [a]D = +35.9◦ (c 0.365,
CHCl3); Rf = 0.29 (CHCl3/MeOH 9:1); IR (KBr): = 3441s, 2947m, 1734m, 1636m, 1458w, 1370w, 1247m,
1027w cm−1; 1H-NMR (400 MHz, CDCl3):
= 6.42 (t, J = 4.6 Hz, 1H, NH), 5.30 (t, J = 3.6 Hz, 1H, 12-H),
β)-N-(2-Piperazin-1-ylethyl)-3-acetyloxy-urs-12-en-28-amide (7). Compound 7 was prepared from 1
7
ν
δ
4.49 (dd, J = 10.4, 5.3 Hz, 1H, 3-H), 3.42–3.32 (m, 1H, 31-Ha), 3.23–3.13 (m, 1H, 31-Hb), 2.93 (t, J = 4.9 Hz,
4H, 34-H, 340-H), 2.49–2.37 (m, 6H, 32-H, 33-H, 330-H), 2.04 (s, 3H, Ac), 2.02–1.80 (m, 5H, 16-Ha, 11-Ha,
11-Hb, 22-Ha, 18-H), 1.80–1.22 (m, 14H, 16-Hb, 15-Ha, 1-Ha, 2-Ha, 2-Hb, 9-H, 6-Ha, 21-Ha, 7-Ha, 22-Hb,
19-H, 6-Hb, 21-Hb, 7-Hb), 1.08 (s, 3H, 27-H), 1.07–0.94 (m, 3H, 1-Hb, 15-Hb, 20-H), 0.96–0.94 (m, 3H,
30-H), 0.93 (s, 3H, 25-H), 0.88 (d, J = 6.5 Hz, 3H, 29-H), 0.86 (s, 3H, 23-H), 0.85 (s, 3H, 24-H), 0.84–0.78
(m, 1H, 5-H), 0.77 (s, 3H, 26-H) ppm; 13C-NMR (101 MHz, CDCl3):
δ = 178.0 (C-28), 171.1 (Ac), 139.7
(C-13), 125.5 (C-12), 81.0 (C-3), 57.1 (C-32), 55.4 (C-5), 54.1 (C-18), 53.9 (C-33), 47.9 (C-17), 47.6 (C-9),
46.1 (C-34), 42.6 (C-14), 39.9 (C-19), 39.7 (C-8), 39.3 (C-20), 38.4 (C-1), 37.8 (C-4), 37.5 (C-22), 37.0 (C-10),
35.8 (C-31), 32.8 (C-7), 31.1 (C-21), 28.2 (C-23), 28.0 (C-15), 25.0 (C-16), 23.7 (C-2), 23.6 (C-11), 23.4 (C-27),
21.4 (Ac), 21.3 (C-30), 18.3 (C-6), 17.5 (C-29), 17.1 (C-26), 16.9 (C-24), 15.7 (C-25) ppm; MS (ESI, MeOH):
m/z = 610 (100 %, [M + H]+); analysis calcd for C38H63N3O3 (609.94): C 74.83, H 10.41, N 6.89; found:
C 74.57, H 10.69, N 6.64.
(3
according to general procedure B using 1,4-diaminobutane. Column chromatography (SiO2,
CHCl3/MeOH/NH4OH 90:10:1) gave
(yield: 79%); m.p. 117–120 ◦C; [ = +33.7◦ (c 0.305, CHCl3);
Rf = 0.34 (CHCl3/MeOH/NH4OH 90:10:1); IR (KBr): = 3440s, 2928m, 1736w, 1636m, 1522w, 1458w,
1370w, 1246m, 1028w cm−1; 1H-NMR (400 MHz, CDCl3):
= 6.03 (t, J = 5.5 Hz, 1H, NH), 5.30 (t, J =
β)-N-(4-Aminobutyl)-3-acetyloxy-urs-12-en-28-amide (8). Compound 8 was prepared from 1
8
α]
D
ν
δ
3.6 Hz, 1H, 12-H), 4.53–4.46 (dd, J = 9.7, 6.2 Hz, 1H, 3-H), 3.41–3.30 (m, 1H, 31-Ha), 3.05–2.94 (m, 1H,
31-Hb), 2.78 (t, J = 6.2 Hz, 2H, 32-Ha, 32-Hb), 2.04 (s, 3H, Ac), 2.02–1.90 (m, 3H, 11-Ha, 11-Hb, 16-Ha),
1.90–1.80 (m, 2H, 18-H, 22-Ha), 1.76–1.20 (m, 18H, 16-Hb, 15-Ha, 1-Ha, 2-Ha, 2-Hb, 9-H, 6-Ha, 34-Ha,

Molecules 2018, 23, 2558
10 of 19
34-Hb, 33-Ha, 33-Hb, 21-Ha, 7-Ha, 19-H, 22-Hb, 6-Hb, 21-Hb, 7-Hb), 1.09 (s, 3H, 27-H), 1.14–1.01 (m,
2H, 1-Hb, 15-Hb), 0.95 (s, 7H, 25-H, 30-H, 20-H), 0.89–0.86 (m, 3H, 29-H), 0.86 (s, 3H, 23-H), 0.85 (s, 3H,
24-H), 0.84–0.80 (m, 1H, 5-H), 0.77 (s, 3H, 26-H) ppm; 13C-NMR (101 MHz, CDCl3):
δ = 178.2 (C-28),
171.1 (Ac), 140.2 (C-13), 125.6 (C-12), 81.0 (C-3), 55.4 (C-5), 54.1 (C-18), 47.8 (C-17), 47.6 (C-9), 42.7
(C-14), 41.8 (C-32), 39.9 (C-19), 39.7 (C-8), 39.4 (C-31), 39.3 (C-20), 38.5 (C-1), 37.8 (C-4), 37.4 (C-22), 37.0
(C-10), 32.8 (C-7), 31.2 (C-21), 30.8 (C-33), 28.2 (C-23), 28.0 (C-15), 26.9 (C-34), 25.0 (C-16), 23.7 (C-2),
23.6 (C-11), 23.4 (C-27), 21.5 (Ac), 21.4 (C-30), 18.3 (C-6), 17.4 (C-29), 17.1 (C-26), 16.9 (C-24), 15.7 (C-25)
ppm; MS (ESI, MeOH): m/z = 569 (100%, [M + H]+); analysis calcd for C36H60N2O3 (568.89): C 76.01,
H 10.63, N 4.92; found: C 75.84, H 10.91, N 4.63.
(3
1
β)-N-[2-(2-Aminoethoxy)ethyl]-3-acetyloxy-urs-12-en-28-amide (9). Compound 9 was prepared from
according to general procedure B using 2,20-oxybis(ethylamine). Column chromatography (SiO2,
CHCl3/MeOH/NH4OH 90:10:0.1) gave
Rf = 0.39 (CHCl3/MeOH 9:1); IR (KBr):
1247s, 1120m, 1027m cm−1; 1H-NMR (500 MHz, CDCl3):
9
(yield: 78%); m.p. 91–94 ◦C; [
= 3424br s, 2927s, 2871s, 1735s, 1640s, 1529m, 1455m, 1370m,
= 6.29 (t, J = 5.0 Hz, 1H, NH), 5.28 (t, J =
α]
D = +18.3◦ (c 0.310, CHCl3);
ν
δ
3.6 Hz, 1H, 12-H), 4.48 (dd, J = 10.9, 5.3 Hz, 1H, 3-H), 3.57–3.44 (m, 5H, 31-Ha, 32-H, 33-H), 3.30–3.22 (m,
1H, 31-Hb), 2.87 (t, J = 5.3 Hz, 2H, 34-H), 2.03 (s, 3H, Ac), 2.01–1.81 (m, 5H, 16-Ha, 11-Ha, 11-Hb, 18-H,
22-Ha), 1.78–1.22 (m, 14H, 16-Hb, 15-Ha, 1-Ha, 2-Ha, 2-Hb, 9-H, 6-Ha, 21-Ha, 7-Ha, 22-Hb, 19-H, 6-Hb,
21-Hb, 7-Hb), 1.08 (s, 3H, 27-H), 1.12–1.00 (m, 2H, 1-Hb, 15-Hb), 0.99–0.90 (m, 4H, 30-H, 20-H), 0.93 (s,
3H, 25-H), 0.86 (d, J = 6.6 Hz, 3H, 29-H), 0.85 (s, 3H, 23-H), 0.84 (s, 3H, 24-H), 0.83–0.80 (m, 1H, 5-H),
0.78 (s, 3H, 26-H) ppm; 13C-NMR (126 MHz, CDCl3):
δ = 178.3 (C-28), 171.1 (Ac), 139.8 (C-13), 125.7
(C-12), 81.0 (C-3), 73.2 (C-33), 69.6 (C-32), 55.4 (C-5), 53.9 (C-18), 47.9 (C-17), 47.6 (C-9), 42.6 (C-14), 42.0
(C-34), 39.9 (C-19), 39.7 (C-8), 39.3 (C-31), 39.2 (C-20), 38.4 (C-1), 37.8 (C-4), 37.3 (C-22), 37.0 (C-10), 32.8
(C-7), 31.0 (C-21), 28.2 (C-23), 28.0 (C-15), 25.0 (C-16), 23.7 (C-2), 23.6 (C-11), 23.4 (C-27), 21.4 (Ac), 21.4
(C-30), 18.3 (C-6), 17.4 (C-29), 17.0 (C-26), 16.8 (C-24), 15.7 (C-25) ppm; MS (ESI, MeOH): m/z = 585
(100 %, [M + H]+); analysis calcd for C36H60N2O4 (584.89): C 73.93, H 10.34, N 4.79; found: C 73.77, H
10.51, N 4.56.
(3
β)-N-(2-Aminoethyl)-3-hydroxy-urs-12-en-28-amide (10). Compound 10 was prepared from 3 according
to general procedure C. Column chromatography (SiO2, CHCl3/MeOH/NH4OH 90:10:0.1) gave
◦
◦
10 (yield: 85%); m.p. 139–142 C (lit.: 145–147 C [17]); [α]
= +38.6◦ (c 0.300, CHCl3); Rf = 0.34
D
(CHCl3/MeOH 9:1); IR (KBr):
ν
= 3425br s, 2926s, 1638m, 1529m, 1454m, 1386w, 1092w, 1046m, 755m
= 6.36 (t, J = 5.4 Hz, 1H, NH), 5.33 (t, J = 3.4 Hz, 1H, 12-H),
cm−1; H-NMR (400 MHz, CDCl3):
δ
1
3.46–3.36 (m, 1H, 31-Ha), 3.21 (dd, J = 11.1, 4.7 Hz, 1H, 3-H), 3.13–3.02 (m, 1H, 31-Hb), 2.82 (t, J = 5.9
Hz, 2H, 32-Ha, 32-Hb), 2.05–1.82 (m, 5H, 16-Ha, 11-Ha, 11-Hb, 18-H, 22-Ha), 1.77–1.23 (m, 14H, 16-Hb,
15-Ha, 1-Ha, 2-Ha, 2-Hb, 9-H, 6-Ha, 21-Ha, 7-Ha, 22-Hb, 19-H, 6-Hb, 21-Hb, 7-Hb), 1.09 (s, 3H, 27-H),
1.07–0.99 (m, 2H, 15-Hb, 1-Hb), 0.98 (s, 3H, 23-H), 0.96–0.93 (m, 4H, 20-H, 30-H), 0.91 (s, 3H, 25-H), 0.87
(d, J = 6.5 Hz, 3H, 29-H), 0.78 (s, 6H, 24-H, 26-H), 0.74–0.69 (m, 1H, 5-H) ppm; 13C-NMR (101 MHz,
CDCl3):
δ = 178.8 (C-28), 139.7 (C-13), 125.9 (C-12), 79.1 (C-3), 55.3 (C-5), 53.9 (C-18), 48.0 (C-17), 47.7
(C-9), 42.6 (C-14), 41.8 (C-31), 41.3 (C-32), 39.9 (C-19), 39.7 (C-8), 39.2 (C-20), 38.9 (C-4), 38.8 (C-1), 37.5
(C-22), 37.1 (C-10), 32.9 (C-7), 31.1 (C-21), 28.3 (C-23), 28.0 (C-15), 27.4 (C-2), 25.0 (C-16), 23.6 (C-11), 23.4
(C-27), 21.4 (C-30), 18.4 (C-6), 17.4 (C-29), 17.1 (C-26), 15.8 (C-24), 15.7 (C-25) ppm; MS (ESI, MeOH):
m/z = 499 (100 %, [M + H]+); analysis calcd for C32H54N2O2 (498.80): C 77.06, H 10.91, N 5.62; found:
C 76.92, H 11.08, N 5.40.
(3
according to general procedure C. Column chromatography (SiO2, CHCl3/MeOH 95:5) gave 11 (yield:
86%). m.p. 270–273 ◦C (decomp.); [ = +38.5◦ (c 0.375, CHCl3); R = 0.44 (CHCl3/MeOH 9:1); IR
(KBr): = 3402br s, 2924s, 2868s, 2684m, 1658s, 1518m, 1460s, 1386m, 1212w, 1138w, 1046m, 1028m, 994m
cm−1; 1H-NMR (500 MHz, CDCl3):
= 7.18 (dd, J = 5.6, 5.6 Hz, 1H, NH), 5.41 (t, J = 3.6 Hz, 1H, 12-H),
β)-N-[2-(Dimethylamino)ethyl]-3-hydroxy-urs-12-en-28-amide (11). Compound 11 was prepared from 4
α
]
D
f
ν
δ
3.78–3.68 (m, 1H, 31-Ha), 3.59–3.49 (m, 1H, 31-Hb), 3.21 (dd, J = 11.0, 4.7 Hz, 1H, 3-H), 3.18–3.13 (m,
2H, 32-H), 2.84 (s, 6H, 33-H, 330-H), 2.20 (d, J = 10.5 Hz, 1H, 18-H), 2.03 (ddd, J = 13.7, 13.7, 4.2 Hz, 1H,

Molecules 2018, 23, 2558
11 of 19
16-Ha), 1.96–1.91 (m, 2H, 11-Ha, 11-Hb), 1.81–1.26 (m, 15H, 22-Ha, 16-Hb, 15-Ha, 1-Ha, 2-Ha, 2-Hb, 6-Ha,
9-H, 22-Hb, 7-Ha, 21-Ha, 19-H, 6-Hb, 7-Hb, 21-Hb), 1.08 (s, 3H, 27-H), 1.07–0.96 (m, 3H, 15-Hb, 20-H,
1-Hb), 0.98 (s, 3H, 23-H), 0.93 (d, J = 6.5 Hz, 3H, 30-H), 0.90 (s, 3H, 25-H), 0.88 (d, J = 6.5 Hz, 3H, 29-H),
0.77 (s, 3H, 24-H), 0.73 (s, 3H, 26-H), 0.72–0.69 (m, 1H, 5-H) ppm; 13C-NMR (126 MHz, CDCl3):
δ =
179.6 (C-28), 138.8 (C-13), 126.2 (C-12), 79.1 (C-3), 58.2 (C-32), 55.3 (C-5), 52.7 (C-18), 48.0 (C-17), 47.7
0
(C-9), 44.2 (C-33), 43.9 (C-33 ), 42.3 (C-14), 39.7 (C-8), 39.7 (C-19), 38.9 (C-1), 38.8 (C-20), 38.7 (C-4), 37.4
(C-22), 37.1 (C-10), 35.1 (C-31), 32.9 (C-7), 31.0 (C-21), 28.3 (C-23), 28.0 (C-15), 27.4 (C-2), 24.6 (C-16),
23.6 (C-27), 23.5 (C-11), 21.3 (C-30), 18.4 (C-6), 17.2 (C-29), 17.2 (C-26), 15.8 (C-24), 15.6 (C-25) ppm; MS
(ESI, MeOH): m/z = 527 (100%, [M + H]+); analysis calcd for C34H58N2O2 (526.85): C 77.51, H 11.10, N
5.32; found: C 77.37, H 11.25, N 5.17.
(3
according to general procedure C. Column chromatography (SiO2, CHCl3/MeOH 95:5) gave 12 (yield:
84%); m.p. 263–266 ◦C (decomp.); [ = +39.8◦ (c 0.445, MeOH); R = 0.40 (CHCl3/MeOH 9:1); IR
(KBr): = 3420br s, 2926s, 2670s, 2616m, 2488m, 2360s, 2342m, 1636m, 1526m, 1456m, 1386m, 1278w,
β)-N-(2-Pyrrolidin-1-ylethyl)-3-hydroxy-urs-12-en-28-amide (12). Compound 12 was prepared from 5
α
]
D
f
ν
1244w, 1092w, 1046m, 998m, 668m cm−1; 1H-NMR (500 MHz, CDCl3):
δ = 7.06 (t, J = 5.5 Hz, 1H, NH),
5.40 (t, J = 3.5 Hz, 1H, 12-H), 3.89–3.77 (m, 2H, 33-Ha, 330-Ha), 3.76–3.66 (m, 1H, 31-Ha), 3.61–3.51 (m,
1H, 31-Hb), 3.27–3.14 (m, 3H, 3-H, 32-H), 2.89–2.77 (m, 2H, 33-Hb, 330-Hb), 2.26–2.17 (m, 2H, 34-Ha,
0
0
34 -Ha), 2.14 (d, J = 11.0 Hz, 1H, 18-H), 2.12–1.97 (m, 3H, 34-Hb, 34 -Hb, 16-Ha), 1.94 (dd, J = 8.8, 3.4 Hz,
2H, 11-Ha, 11-Hb), 1.81–1.22 (m, 15H, 22-Ha, 16-Hb, 15-Ha, 1-Ha, 2-Ha, 2-Hb, 6-Ha, 9-H, 22-Hb, 7-Ha,
21-Ha, 19-H, 6-Hb, 21-Hb, 7-Hb), 1.08 (s, 3H, 27-H), 1.07–0.96 (m, 3H, 15-Hb, 20-H, 1-Hb), 0.98 (s, 3H,
23-H), 0.94 (d, J = 6.3 Hz, 3H, 30-H), 0.91 (s, 3H, 25-H), 0.88 (d, J = 6.4 Hz, 3H, 29-H), 0.78 (s, 3H, 24-H),
0.73 (s, 3H, 26-H), 0.73–0.69 (m, 1H, 5-H) ppm; 13C-NMR (126 MHz, CDCl3):
δ = 179.6 (C-28), 138.9
(C-13), 126.2 (C-12), 79.2 (C-3), 55.4 (C-32), 55.3 (C-5), 54.9 (C-33), 54.6 (C-330), 52.9 (C-18), 47.9 (C-17),
47.7 (C-9), 42.4 (C-14), 39.8 (C-19), 39.7 (C-8), 38.9 (C-1), 38.9 (C-20), 38.7 (C-4), 37.4 (C-22), 37.1 (C-10),
36.1 (C-31), 32.9 (C-7), 31.0 (C-21), 28.3 (C-23), 28.0 (C-15), 27.4 (C-2), 24.7 (C-16), 23.6 (C-27), 23.5 (C-34,
0
C-34 ), 23.4 (C-11), 21.4 (C-30), 18.5 (C-6), 17.3 (C-29), 17.2 (C-26), 15.8 (C-24), 15.6 (C-25) ppm; MS (ESI,
MeOH): m/z = 553 (100%, [M + H]+); analysis calcd for C36H60N2O2 (552.89): C 78.21, H 10.94, N 5.07;
found: C78.02, H 11.09, N 4.83.
(3
according to general procedure C. Column chromatography (SiO2, CHCl3/MeOH 95:5) gave 13 (yield:
93%); m.p. 120–124 ◦C; [ ]D = +40.5◦ (c 0.350, CHCl3); Rf = 0.23 (CHCl3/MeOH 95:5); IR (KBr):
β)-N-(2-Piperidin-1-ylethyl)-3-hydroxy-urs-12-en-28-amide (13). Compound 13 was prepared from 6
α
ν =
3416br s, 2934s, 2870m, 2854m, 1636s, 1512m, 1456m, 1378m, 1358w, 1304w, 1272w, 1256w, 1156w, 1130w,
1
1092w, 1046m, 998m, 754m cm−1; H-NMR (400 MHz, CDCl3):
δ = 6.62–6.54 (m, 1H, NH), 5.31 (t, J
= 3.6 Hz, 1H, 12-H), 3.42–3.32 (m, 1H, 31-Ha), 3.25–3.16 (m, 2H, 3-H, 31-Hb), 2.50–2.35 (m, 6H, 32-H,
33-H, 330-H), 2.02–1.80 (m, 5H, 16-Ha, 11-Ha, 11-Hb, 18-H, 22-Ha), 1.78–1.20 (m, 20H, 16-Hb, 15-Ha,
1-Ha, 34-H, 340-H, 35-H, 9-H, 6-Ha, 21-Ha, 7-Ha, 2-Ha, 2-Hb, 22-Hb, 19-H, 6-Hb, 21-Hb, 7-Hb), 1.08 (s,
3H, 27-H), 1.07–0.97 (m, 3H, 15-Hb, 1-Hb, 20-H), 0.98 (s, 3H, 23-H), 0.96–0.93 (m, 3H, 30-H), 0.91 (s, 3H,
25-H), 0.87 (d, J = 6.4 Hz, 3H, 29-H), 0.77 (s, 6H, 24-H, 26-H), 0.74–0.69 (m, 1H, 5-H) ppm; 13C-NMR
(101 MHz, CDCl3):
δ = 178.0 (C-28), 139.4 (C-13), 125.8 (C-12), 79.1 (C-3), 57.2 (C-32), 55.3 (C-5), 54.4
(C-33, C-330), 53.9 (C-18), 47.7 (C-17), 47.7 (C-9), 42.5 (C-14), 39.9 (C-19), 39.7 (C-8), 39.2 (C-20), 38.9
(C-1), 38.8 (C-4), 37.5 (C-22), 37.1 (C-10), 35.9 (C-31), 32.9 (C-7), 31.1 (C-21), 28.3 (C-23), 28.0 (C-15), 27.3
(C-35), 26.0 (C-34, C-340), 24.9 (C-16), 24.4 (C-2), 23.5 (C-11), 23.4 (C-27), 21.4 (C-30), 18.4 (C-6), 17.4
(C-29), 17.1 (C-26), 15.8 (C-24), 15.6 (C-25) ppm; MS (ESI, MeOH): m/z = 567 (100%, [M + H]+); analysis
calcd for C37H62N2O2 (566.92): C 78.39, H 11.02, N 4.94; found: C 78.11, H 11.19, N 4.80.
(3
according to general procedure C. Column chromatography (SiO2, CHCl3/MeOH 9:1) gave 14 (yield:
88%); m.p. 214–217 ◦C (lit.: 217–220 ◦C [18]); [ = +32.2◦ (c 0.335, CHCl3); R = 0.20 (CHCl3/MeOH
9:1); IR (KBr): = 3420br s, 2928s, 2870m, 2496w, 1630s, 1528m, 1458m, 1384s, 1178w, 1138w, 1092w,
1046m, 1030m, 998m cm−1; 1H-NMR (400 MHz, CD3OD):
= 5.37 (t, J = 3.6 Hz, 1H, 12-H), 3.42–3.31 (m,
β)-N-(2-Piperazin-1-ylethyl)-3-hydroxy-urs-12-en-28-amide (14). Compound 14 was prepared from 7
α
]
D
f
ν
δ

Molecules 2018, 23, 2558
12 of 19
1H, 31-Ha), 3.28–3.18 (m, 2H, 31-Hb, 3-H), 3.16 (t, J = 5.0 Hz, 4H, 34-H, 34‘-H), 2.77–2.61 (m, 4H, 33-H,
33‘-H), 2.54 (t, J = 6.6 Hz, 2H, 32-H), 2.17–1.89 (m, 4H, 18-H, 16-Ha, 11-Ha, 11-Hb), 1.86–1.30 (m, 15H,
15-Ha, 22-Ha, 16-Hb, 1-Ha, 2-Ha, 2-Hb, 9-H, 6-Ha, 7-Ha, 22-Hb, 21-Ha, 19-H, 6-Hb, 21-Hb, 7-Hb), 1.16
(s, 3H, 27-H), 1.15–1.02 (m, 3H, 15-Hb, 1-Hb, 20-H), 1.02–0.97 (m, 3H, 30-H), 1.01 (s, 3H, 23-H), 0.99 (s,
3H, 25-H), 0.95 (d, J = 6.4 Hz, 3H, 29-H), 0.84 (s, 3H, 26-H), 0.81 (s, 3H, 24-H), 0.80–0.76 (m, 1H, 5-H)
ppm; 13C-NMR (101 MHz, CD3OD):
δ = 180.3 (C-28), 140.1 (C-13), 127.0 (C-12), 79.6 (C-3), 57.8 (C-32),
56.7 (C-5), 54.3 (C-18), 51.8 (C-33, C-33‘), 49.0 (C-17), 48.9 (C-9), 45.3 (C-34, C-34‘), 43.4 (C-14), 40.9
(C-8), 40.9 (C-19), 40.3 (C-20), 39.9 (C-1), 39.8 (C-4), 38.8 (C-22), 38.1 (C-10), 37.4 (C-31), 34.1 (C-7), 31.9
(C-21), 29.0 (C-15), 28.8 (C-23), 27.9 (C-2), 25.3 (C-16), 24.5 (C-11), 24.0 (C-27), 21.6 (C-30), 19.4 (C-6),
18.0 (C-26), 17.7 (C-29), 16.4 (C-24), 16.1 (C-25) ppm; MS (ESI, MeOH): m/z = 568 (100%, [M + H]+);
analysis calcd for C36H61N3O2 (567.90): C 76.14, H 10.83, N 7.40; found: C 75.84, H 11.03, N 7.25.
(3
to general procedure C. Column chromatography (SiO2, CHCl3/MeOH 9:1) gave 15 (yield: 87%); m.p.
177–180 ◦C; [ ]D = +42.2◦ (c 0.315, DMSO); Rf = 0.33 (CHCl3/MeOH 88:12); IR (KBr):
= 3424br m,
2927m, 1629w, 1534w, 1384s, 1029w cm−1; 1H-NMR (400 MHz, DMSO-d6):
= 7.79–7.54 (m, 2H, NH2),
β)-N-(4-Aminobutyl)-3-hydroxy-urs-12-en-28-amide (15). Compound 15 was prepared from 8 according
α
ν
δ
7.17 (t, J = 5.7 Hz, 1H, NH), 5.19 (t, J = 3.6 Hz, 1H, 12-H), 4.28 (s, 1H, OH), 3.07–2.90 (m, 3H, 3-H, 31-H),
2.76 (t, J = 7.4 Hz, 2H, 32-H), 2.15 (d, J = 10.9 Hz, 1H, 18-H), 1.97–1.65 (m, 4H, 16-Ha, 11-Ha, 11-Hb,
15-Ha), 1.65–1.17 (m, 18H, 16-Hb, 22-Ha, 1-Ha, 34-Ha, 34-Hb, 6-Ha, 9-H, 2-Ha, 2-Hb, 7-Ha, 22-Hb, 21-Ha,
33-Ha, 33-Hb, 19-H, 6-Hb, 21-Hb, 7-Hb), 1.03 (s, 3H, 27-H), 0.95–0.88 (m, 6H, 15-Hb, 1-Hb, 30-H, 20-H),
0.89 (s, 3H, 23-H), 0.85 (s, 3H, 25-H), 0.82 (d, J = 6.4 Hz, 3H, 29-H), 0.67 (s, 6H, 24-H, 26-H), 0.67–0.64
(m, 1H, 5-H) ppm; 13C-NMR (101 MHz, DMSO-d6):
δ = 176.2 (C-28), 138.4 (C-13), 124.5 (C-12), 76.8
(C-3), 54.8 (C-5), 51.9 (C-18), 47.0 (C-9), 46.5 (C-17), 41.6 (C-14), 39.1 (C-8), 38.8 (C-19), 38.7 (C-32), 38.5
(C-20), 38.4 (C-4), 38.2 (C-1), 38.0 (C-31), 37.1 (C-22), 36.5 (C-10), 32.7 (C-7), 30.4 (C-21), 28.3 (C-23), 27.4
(C-15), 27.0 (C-2), 26.0 (C-33), 24.6 (C-34), 23.5 (C-16), 23.3 (C-27), 22.9 (C-11), 21.1 (C-30), 18.0 (C-6),
17.1 (C-29), 16.8 (C-26), 16.1 (C-24), 15.2 (C-25) ppm; MS (ESI, MeOH): m/z = 527 (100 %, [M + H]+),
1053 (18 %, [2M + H]+); analysis calcd for C34H58N2O2 (526.85): C 77.51, H 11.10, N 5.32; found: C
77.39, H 11.30, N 5.16.
(3β)-N-[2-(2-Aminoethoxy)ethyl]-3-acetyloxy-urs-12-en-28-amide (16). Compound 16 was prepared from 9
according to general procedure C. Column chromatography (SiO2, CHCl3/MeOH 9:1) gave 16 (yield:
86%). m.p. 126–129 ◦C; [
α
]
= +34.3◦ (c 0.305, CHCl3); R = 0.20 (CHCl3/MeOH 9:1); IR (KBr):
ν
=
D
f
3426br s, 2926s, 2870m, 1636m, 1534m, 1534m, 1456w, 1384w, 1118w, 1044w, 1030w cm−1; H-NMR
1
(500 MHz, CD3OD):
δ = 5.33 (t, J = 3.7 Hz, 1H, 12-H), 3.62 (dd, J = 5.7, 4.7 Hz, 2H, 33-H), 3.52 (t, J =
5.9 Hz, 2H, 32-H), 3.44–3.37 (m, 1H, 31-Ha), 3.34–3.24 (m, 1H, 31-Hb), 3.16 (dd, J = 11.3, 4.7 Hz, 1H,
3-H), 3.03 (dd, J = 5.7, 4.6 Hz, 2H, 34-H), 2.16–1.91 (m, 4H, 18-H, 16-Ha, 11-Ha, 11-Hb), 1.84–1.27 (m,
15H, 15-Ha, 22-Ha, 1-Ha, 16-Hb, 2-Ha, 2-Hb, 9-H, 6-Ha, 7-Ha, 22-Hb, 21-Ha, 19-H, 6-Hb, 21-Hb, 7-Hb),
1.13 (s, 3H, 27-H), 1.11–0.98 (m, 3H, 15-Hb, 1-Hb, 20-H), 0.98–0.95 (m, 3H, 30-H), 0.98 (s, 3H, 23-H),
0.96 (s, 3H, 25-H), 0.91 (d, J = 6.4 Hz, 3H, 29-H), 0.81 (s, 3H, 26-H), 0.78 (s, 3H, 24-H), 0.77–0.73 (m, 1H,
5-H) ppm; 13C-NMR (126 MHz, CD3OD):
δ = 180.6 (C-28), 140.0 (C-13), 127.1 (C-12), 79.6 (C-3), 70.8
(C-32), 68.9 (C-33), 56.7 (C-5), 54.2 (C-18), 49.2 (C-17), 48.9 (C-9), 43.3 (C-14), 40.9 (C-8), 40.9 (C-34), 40.8
(C-19), 40.3 (C-20), 40.2 (C-31), 40.0 (C-1), 39.8 (C-4), 38.8 (C-22), 38.1 (C-10), 34.2 (C-7), 31.9 (C-21), 29.0
(C-15), 28.8 (C-23), 27.9 (C-2), 25.3 (C-16), 24.4 (C-11), 24.0 (C-27), 21.6 (C-30), 19.4 (C-6), 17.9 (C-29),
17.7 (C-26), 16.4 (C-24), 16.1 (C-25) ppm; MS (ESI, MeOH): m/z = 543 (100%, [M + H]+); analysis calcd
for C34H58N2O3 (542.85): C 75.23, H 10.77, N 5.16; found: C 75.02, H 10.98, N 5.02.
(3
β)-N-(2-Aminoethyl)-3-acetyloxy-lup-20(29)-en-28-amide (17). Compound 17 was prepared from
2
according to general procedure B using ethylened◦iamine. Column chromatography (SiO2,
CHCl3/MeOH 9:1) gave 17 (yield: 83%); m.p. 152–154 C; [
α]
D
= +8.4◦ (c 0.330, CHCl3); R = 0.38
f
(CHCl3/MeOH 9:1); IR (KBr):
cm−1; 1H-NMR (400 MHz, CDCl3):
(m, 1H, 29-Hb), 4.45 (dd, J = 10.0, 6.2 Hz, 1H, 3-H), 3.40–3.33 (m, 2H, 31-H), 3.09 (ddd, J = 11.0, 11.0, 4.0
ν
= 3442br s, 2946s, 1734m, 1638m, 1522m, 1452m, 1376m, 1248s, 1030m
δ
= 6.39 (t, J = 5.5 Hz, 1H, NH), 4.73–4.70 (m, 1H, 29-Ha), 4.60–4.57

Molecules 2018, 23, 2558
13 of 19
Hz, 1H, 19-H), 2.90 (t, J = 5.9 Hz, 2H, 32-H), 2.42 (ddd, J = 12.7, 12.7, 3.4 Hz, 1H, 13-H), 2.03 (s, 3H, Ac),
2.01–1.68 (m, 4H, 16-Ha, 21-Ha, 22-Ha,12-Ha), 1.67 (s, 3H, 30-Ha), 1.66–1.07 (m, 16H, 22-Hb, 2-Ha, 2-Hb,
18-H, 16-Hb, 15-Ha, 6-Ha, 1-Ha, 11-Ha, 6-Hb, 21-Hb, 7-Ha, 7-Hb, 9-H, 11-Hb, 15-Hb), 1.05–0.88 (m, 2H,
12-Hb, 1-Hb), 0.95 (s, 3H, 27-H), 0.92 (s, 3H, 26-H), 0.83 (s, 6H, 25-H, 23-H), 0.82 (s, 3H, 24-H), 0.80–0.74
(m, 1H, 5-H) ppm; 13C-NMR (101 MHz, CDCl3):
δ = 177.2 (C-28), 171.1 (Ac), 150.9 (C-20), 109.6 (C-29),
81.1 (C-3), 55.9 (C-17), 55.6 (C-5), 50.7 (C-9), 50.3 (C-18), 47.0 (C-19), 42.6 (C-14), 41.5 (C-32), 40.9 (C-8),
40.8 (C-31), 38.6 (C-1, C-22), 37.9 (C-4), 37.9 (C-13), 37.3 (C-10), 34.5 (C-7), 33.8 (C-16), 31.1 (C-21), 29.6
(C-15), 28.1 (C-23), 25.7 (C-12), 23.8 (C-2), 21.5 (Ac), 21.1 (C-11), 19.6 (C-30), 18.3 (C-6), 16.6 (C-24), 16.4
(C-25), 16.3 (C-26), 14.8 (C-27) ppm; MS (ESI, MeOH): m/z = 541 (100 %, [M + H]+); analysis calcd for
C34H56N2O3 (540.83): C 75.51, H 10.44, N 5.18; found: C 75.35, H 10.67, N 5.02.
(3
from
chromatography (SiO2, CHCl3/MeOH 95:5) gave 18 (yield: 94%); m.p. 108–110 ◦C; [
0.320, CHCl3); Rf = 0.51 (CHCl3/MeOH 9:1); IR (KBr):
1375m, 1246s, 1195w, 1029m, 979m cm−1; 1H-NMR (500 MHz, CDCl3):
β)-N-[2-(Dimethylamino)ethyl]-3-acetyloxy-lup-20(29)-en-28-amide (18). Compound 18 was prepared
2
according to general procedure B using N,N-dimethylethylenediamine.
Column
]D = +16.4◦ (c
α
ν
= 3420br s, 2945s, 2869m, 1736s, 1641m, 1456s,
= 6.24 (t, J = 4.7 Hz, 1H, NH),
δ
4.74–4.72 (m, 1H, 29-Ha), 4.60–4.58 (m, 1H, 29-Hb), 4.46 (dd, J = 10.4, 5.9 Hz, 1H, 3-H), 3.40–3.24 (m,
2H, 31-H), 3.11 (ddd, J = 11.0, 11.0, 4.2 Hz, 1H, 19-H), 2.47–2.38 (m, 3H, 32-H + 13-H), 2.26 (s, 6H, 33-H,
330-H), 2.03 (s, 3H, Ac), 2.03–1.89 (m, 2H, 16-Ha, 21-Ha), 1.80–1.74 (m, 1H, 22-Ha), 1.73–1.63 (m, 2H,
12-Ha, 22-Hb), 1.68 (s, 3H, 30-H), 1.63–1.11 (m, 15H, 2-Ha, 2-Hb, 18-H, 16-Hb, 15-Ha, 6-Ha, 11-Ha, 1-Ha,
6-Hb, 7-Ha, 7-Hb, 21-Hb, 9-H, 11-Hb, 15-Hb), 1.05–0.94 (m, 2H, 12-Hb, 1-Hb), 0.96 (s, 3H, 27-H), 0.94
(s, 3H, 26-H), 0.83 (s, 6H, 23-H, 25-H), 0.82 (s, 3H, 24-H), 0.80–0.76 (m, 1H, 5-H) ppm; 13C-NMR (126
MHz, CDCl3):
δ = 176.5 (C-28), 171.1 (Ac), 151.2 (C-20), 109.5 (C-29), 81.1 (C-3), 58.3 (C-32), 55.9 (C-17),
55.6 (C-5), 50.7 (C-9), 50.2 (C-18), 47.1 (C-19), 45.3 (C-33, C-330), 42.7 (C-14), 40.9 (C-8), 38.6 (C-22), 38.6
(C-1), 38.0 (C-13), 38.0 (C-4), 37.3 (C-10), 36.6 (C-31), 34.5 (C-7), 33.8 (C-16), 31.1 (C-21), 29.6 (C-15), 28.1
(C-23), 25.8 (C-12), 23.9 (C-2), 21.5 (Ac), 21.1 (C-11), 19.6 (C-30), 18.4 (C-6), 16.6 (C-24), 16.4 (C-25), 16.3
(C-26), 14.8 (C-27) ppm; MS (ESI, MeOH): m/z = 569 (100%, [M + H]+); analysis calcd for C26H60N2O3
(568.89): C 76.01, H 10.63, N 4.92; found: C 75.77, H 10.84, N 4.63.
(3
2
β
)-N-(2-Pyrrolidin-1-ylethyl)-3-acetyloxy-lup-20(29)-en-28-amide (19). Compound 19 was prepared from
according to general procedure B using 1-(2-aminoethyl)-pyrrolidine. Column chromatography
]D = +11.7◦ (c 0.330, CHCl3); Rf
=3422br m, 2946s, 1734m, 1640m, 1451m, 1384s, 1247s, 1029m,
979m cm−1; 1H-NMR (400 MHz, CDCl3):
= 7.23 (t, J = 5.5 Hz, 1H, NH), 4.72–4.70 (m, 1H, 29-Ha),
(SiO2, CHCl3/MeOH 95:5) gave 19 (yield: 86%); m.p. 143–145 ◦C; [
α
= 0.53 (CHCl3/MeOH 9:1); IR (KBr):
ν
δ
4.58–4.56 (m, 1H, 29-Hb), 4.44 (dd, J = 10.8, 5.5 Hz, 1H, 3-H), 3.68–3.56 (m, 2H, 31-H), 3.47–3.27 (m, 4H,
0
33-H, 33 -H), 3.24 (t, J = 6.1 Hz, 2H, 32-H), 3.05 (ddd, J = 10.9, 10.9, 4.2 Hz, 1H, 19-H), 2.39 (ddd, J = 12.8,
12.8, 3.5 Hz, 1H, 13-H), 2.13–2.04 (m, 5H, 34-H, 340-H, 16-Ha), 2.02 (s, 3H, Ac), 1.89–1.76 (m, 2H, 21-Ha,
22-Ha), 1.66 (s, 3H, 30-H), 1.71–1.11 (m, 17H, 12-Ha, 1-Ha, 2-Ha, 2-Hb, 18-H, 16-Hb, 6-Ha, 22-Hb, 11-Ha,
21-Hb, 7-Ha, 7-Hb, 15-Ha, 6-Hb, 9-H, 11-Hb, 15-Hb), 1.03–0.91 (m, 2H, 12-Hb, 1-Hb), 0.93 (s, 3H, 27-H),
0.89 (s, 3H, 26-H), 0.82 (s, 6H, 23-H, 25-H), 0.81 (s, 3H, 24-H), 0.78–0.75 (m, 1H, 5-H) ppm; 13C-NMR
(101 MHz, CDCl3):
δ
= 177.8 (C-28), 171.1 (Ac), 151.0 (C-20), 109.6 (C-29), 81.1 (C-3), 55.9 (C-17), 55.6
0
(C-5), 55.5 (C-32), 54.8 (C-33, C-33 ), 50.6 (C-9), 50.3 (C-18), 47.0 (C-19), 42.6 (C-14), 40.9 (C-8), 38.5 (C-1),
38.2 (C-22), 37.9 (C-13), 37.9 (C-4), 37.3 (C-10), 36.3 (C-31), 34.5 (C-7), 33.2 (C-16), 31.0 (C-21), 29.6 (C-15),
28.1 (C-23), 25.7 (C-12), 23.8 (C-2), 23.4 (C-34, C-340), 21.4 (Ac), 21.1 (C-11), 19.5 (C-30), 18.3 (C-6), 16.6
(C-24), 16.3 (C-25), 16.3 (C-26), 14.7 (C-27) ppm; MS (ESI, MeOH): m/z = 595 (100%, [M + H]+); analysis
calcd for C38H62N2O3 (594.93): C 76.72, H 10.50, N 4.71; found: C 76.50, H 10.74, N 4.51.
(3
β
)-N-(2-Piperidin-1-ylethyl)-3-acetyloxy-lup-20(29)-en-28-amide (20). Compound 20 was prepared from
according to general procedure B using 1-(2-aminoethyl)-piperidine. Column chromatography (SiO2,
]D = +14.1◦ (c 0.340, CHCl3); Rf = 0.25
= 3424br s, 2942s, 2968m, 1736s, 1638s, 1508m, 1452m, 1376m, 1246s,
1154w, 1128w, 1028m cm−1; 1H-NMR (400 MHz, CDCl3):
= 6.52–6.39 (m, 1H, NH), 4.75–4.70 (m, 1H,
2
CHCl3/MeOH 95:5) gave 20 (yield: 81%); m.p. 124–127 ◦C; [
α
(CHCl3/MeOH 95:5); IR (KBr):
ν
δ

Molecules 2018, 23, 2558
14 of 19
29-Ha), 4.61–4.56 (m, 1H, 29-Hb), 4.46 (dd, J = 9.8, 6.5 Hz, 1H, 3-H), 3.41–3.25 (m, 2H, 31-Ha, 31-Hb), 3.08
(ddd, J = 11.1, 10.9, 3.9 Hz, 1H, 19-H), 2.53–2.40 (m, 6H, 32-H, 33-H, 330-H), 2.35 (ddd, J = 12.4, 12.3, 3.6
Hz, 1H, 13-H), 2.03 (s, 3H, Ac), 2.12–1.89 (m, 2H, 16-Ha, 21-Ha), 1.83–1.74 (m, 1H, 22-Ha), 1.68 (s, 3H,
30-H), 1.72–1.54 (m, 9H, 12-Ha, 1-Ha, 2-Ha, 2-Hb, 18-H, 34-H, 340-H), 1.55–1.15 (m, 13H, 16-Hb, 15-Ha,
6-Ha, 35-H, 11-Ha, 22-Hb, 21-Hb, 6-Hb, 7-Ha, 7-Hb, 9-H, 11-Hb), 1.15–1.09 (m, 1H, 15-Hb), 1.08–0.93
(m, 2H, 12-Hb, 1-Hb), 0.96 (s, 3H, 27-H), 0.92 (s, 3H, 26-H), 0.83 (s, 6H, 25-H, 23-H), 0.82 (s, 3H, 24-H),
0.80–0.74 (m, 1H, 5-H) ppm; 13C-NMR (101 MHz, CDCl3):
δ
= 176.3 (C-28), 171.1 (Ac), 151.1 (C-20),
0
109.5 (C-29), 81.1 (C-3), 57.1 (C-32), 56.0 (C-17), 55.6 (C-5), 54.3 (C-33, C-33 ), 50.6 (C-9), 50.0 (C-18), 47.2
(C-19), 42.7 (C-14), 40.9 (C-8), 38.5 (C-1), 38.5 (C-22), 38.1 (C-13), 37.9 (C-4), 37.3 (C-10), 35.7 (C-31),
34.5 (C-7), 33.8 (C-16), 31.1 (C-21), 29.6 (C-15), 28.1 (C-23), 26.1 (C-34, C-340), 25.8 (C-12), 24.4 (C-35),
23.8 (C-2), 21.4 (Ac), 21.1 (C-11), 19.6 (C-30), 18.4 (C-6), 16.6 (C-24), 16.4 (C-25), 16.3 (C-26), 14.8 (C-27)
ppm; MS (ESI, MeOH): m/z = 609 (100%, [M + H]+); analysis calcd for C39H64N2O3 (608.95): C 76.92,
H 10.59, N 4.60; found:
(3
β
)-N-(2-Piperazin-1-ylethyl)-3-acetyloxy-lup-20(29)-en-28-amide (21). Compound 21 was prepared from
2
according to general procedure B using 1-(2-aminoethyl)-piperazine. Column chromatography (SiO2,
◦
CHCl3/MeOH/NH4OH 90:11:0.5) gave 21 (yield: 84%); m.p. 107–110 C; [
CHCl3); Rf = 0.44 (CHCl3/MeOH/NH4OH 90:10:1);IR (KBr): = 3422br s, 2944s, 2870m, 1734s, 1638s,
1522m, 1452m, 1374m, 1318w, 1248s, cm−1; 1194w, 1138w, 1028m cm−1; 1H-NMR (400 MHz, CDCl3):
α]
= +13.7◦ (c 0.335,
D
ν
δ
= 6.22 (t, J = 4.8 Hz, 1H, NH), 4.75–4.70 (m, 1H, 29-Ha), 4.61–4.58 (m, 1H, 29-Hb), 4.46 (dd, J = 9.7, 6.5
Hz, 1H, 3-H), 3.41–3.23 (m, 2H, 31-H), 3.08 (ddd, J = 11.1, 11.1, 3.8 Hz, 1H, 19-H), 2.92 (t, J = 4.9 Hz, 4H,
34-H, 340-H), 2.55–2.41 (m, 6H, 32-H, 33-H, 330-H), 2.36 (ddd, J = 12.4, 12.4, 3.6 Hz, 1H, 13-H), 2.03 (s,
3H, Ac), 2.05–1.89 (m, 2H, 16-Ha, 21-Ha), 1.68 (s, 3H, 30-H), 1.81–1.53 (m, 6H, 22-Ha, 12-Ha, 1-Ha, 18-H,
2-Ha, 2-Hb), 1.52–1.19 (m, 11H, 16-Hb, 15-Ha, 6-Ha, 11-Ha, 22-Hb, 6-Hb, 21-Hb, 7-Ha, 7-Hb, 9-H, 11-Hb),
1.20–0.90 (m, 3H, 15-Hb, 12-Hb, 1-Hb), 0.96 (s, 3H, 27-H), 0.91 (s, 3H, 26-H), 0.83 (s, 6H, 23-H, 25-H),
0.82 (s, 3H, 24-H), 0.80–0.74 (m, 1H, 5-H) ppm; 13C-NMR (101 MHz, CDCl3):
δ = 176.3 (C-28), 171.1
(Ac), 151.0 (C-20), 109.6 (C-29), 81.1 (C-3), 57.1 (C-32), 56.0 (C-17), 55.6 (C-5), 53.7 (C-33, C-330), 50.6
0
(C-9), 50.0 (C-18), 47.2 (C-19), 46.1 (C-34, C-34 ), 42.7 (C-14), 40.9 (C-8), 38.5 (C-1, C-22), 38.1 (C-13), 37.9
(C-4), 37.3 (C-10), 35.6 (C-31), 34.5 (C-7), 33.8 (C-16), 31.1 (C-21), 29.6 (C-15), 28.1 (C-23), 25.7 (C-12),
23.8 (C-2), 21.5 (Ac), 21.1 (C-11), 19.6 (C-30), 18.3 (C-6), 16.6 (C-24), 16.4 (C-25), 16.3 (C-26), 14.8 (C-27)
ppm; MS (ESI, MeOH): m/z = 610 (100%, [M + H]+); analysis calcd for C38H63N3O3 (609.94): C 74.83,
H 10.41, N 6.89; found: C 74.65, H 10.69, N 6.64.
(3
β
)-N-(4-Aminobutyl)-3-acetyloxy-lup-20(29)-en-28-amide (22). Compound 22 was prepared from
2
according to general procedure B using 1,4-diaminobutane. Column chromatography (SiO2,
◦
CHCl3/MeOH/NH4OH 90:11:0.5) gave 22 (yield: 84%); m.p. 133–135 C; [
CHCl3); Rf = 0.33 (CHCl3/MeOH/NH4OH 90:10:1); IR (KBr): = 3422br s, 2944s, 2868m, 1736s, 1638s,
1522m, 1452m, 1374m, 1248s, 1028m, 980m, 754m cm−1; 1H-NMR (400 MHz, CDCl3):
= 5.94 (t, J =
α]
= +7.4◦ (c 0.350,
D
ν
δ
5.8 Hz, 1H, NH), 4.75–4.69 (m, 1H, 29-Ha), 4.61–4.55 (m, 1H, 29-Hb), 4.45 (dd, J = 8.7, 7.6 Hz, 1H, 3-H),
3.35–3.15 (m, 2H, 31-Ha, 31-Hb), 3.11 (ddd, J = 11.0, 4.0 Hz, 4.0 Hz, 1H, 19-H), 2.84–2.73 (m, 2H, 32-Ha,
32-Hb), 2.45 (ddd, J = 12.4, 3.6 Hz, 3.6 Hz, 1H, 13-H), 2.03 (s, 3H, Ac), 2.00–1.80 (m, 2H, 21-Ha, 16-Ha),
1.67 (s, 3H, 30-H), 1.77–1.18 (m, 21H, 22-Ha, 12-Ha, 1-Ha, 2-Ha, 2-Hb, 34-Ha, 34-Hb, 18-H, 33-Ha, 33-Hb,
16-Hb, 6-Ha, 15-Ha, 11-Ha, 22-Hb, 6-Hb, 21-Hb, 7-Ha, 7-Hb, 11-Hb, 9-H), 1.16–1.08 (m, 1H, 15-Hb),
1.04–0.90 (m, 2H, 12-Hb, 1-Hb), 0.95 (s, 3H, 27-H), 0.92 (s, 3H, 26-H), 0.84 (s, 3H, 25-H), 0.83 (s, 3H, 23-H),
0.82 (s, 3H, 24-H), 0.80–0.74 (m, 1H, 5-H) ppm; 13C-NMR (101 MHz, CDCl3):
δ = 176.4 (C-28), 171.1
(Ac), 151.1 (C-20), 109.5 (C-29), 81.1 (C-3), 55.8 (C-17), 55.6 (C-5), 50.7 (C-9), 50.3 (C-18), 46.9 (C-19), 42.6
(C-14), 41.4 (C-32), 40.9 (C-8), 39.1 (C-31), 38.6 (C-22), 38.5 (C-1), 38.0 (C-4), 37.9 (C-13), 37.3 (C-10), 34.5
(C-7), 33.9 (C-16), 31.1 (C-21), 29.9 (C-33), 29.6 (C-15), 28.1 (C-23), 27.3 (C-34), 25.8 (C-12), 23.9 (C-2),
21.5 (Ac), 21.1 (C-11), 19.6 (C-30), 18.3 (C-6), 16.6 (C-24), 16.4 (C-25), 16.3 (C-26), 14.8 (C-27) ppm; MS
(ESI, MeOH): m/z = 569 (100%, [M + H]+); analysis calcd for C36H60N2O3 (568.89): C 76.01, H 10.63, N
4.92; found: C75.81, H 10.77, N 4.75.

Molecules 2018, 23, 2558
15 of 19
(3
from
(SiO2, CHCl3/MeOH 9:1) gave 23 (yield: 81%); m.p. 109–112 ◦C; [
β
)-N-[2-(2-Aminoethoxy)ethyl]-3-acetyloxy-lup-20(29)-en-28-amide (23). Compound 23 was prepared
according to general procedure B using 2,20-oxybis(ethylamine). Column chromatography
= +38.4◦ (c 0.325, CHCl3); R
2
α
]
D
f
= 0.58 (CHCl3/MeOH/NH4OH 90:10:1); IR (KBr):
1248m, 1029w cm−1; 1H-NMR (500 MHz, CDCl3):
ν
= 3448br s, 2944m, 1734m, 1637m, 1527w, 1375w,
= 6.09 (t, J = 5.4 Hz, 1H, NH), 4.74–4.70 (m, 1H,
δ
29-Ha), 4.60–4.56 (m, 1H, 29-Hb), 4.46 (dd, J = 10.6, 5.8 Hz, 1H, 3-H), 3.58–3.44 (m, 5H, 32-H, 33-H,
31-Ha), 3.43–3.35 (m, 1H, 31-Hb), 3.10 (ddd, J = 11.1, 11.0, 4.2 Hz, 1H, 19-H), 2.88 (t, J = 5.2 Hz, 2H, 34-H),
2.43 (ddd, J = 12.9, 11.5, 3.7 Hz, 1H, 13-H), 2.03 (s, 3H, Ac), 2.00–1.88 (m, 2H, 16-Ha, 21-Ha), 1.78–1.72 (m,
1H, 22-Ha), 1.67 (s, 3H, 30-H), 1.72–1.17 (m, 16H, 12-Ha, 1-Ha, 2-Ha, 2-Hb, 18-H, 16-Hb, 6-Ha, 15-Ha,
22-Hb, 11-Ha, 6-Hb, 21-Hb, 7-Ha, 7-Hb, 9-H, 11-Hb), 1.16–1.09 (m, 1H, 15-Hb), 1.05–0.95 (m, 2H, 12-Hb,
1-Hb), 0.95 (s, 3H, 27-H), 0.93 (s, 3H, 26-H), 0.83 (s, 3H, 25-H), 0.83 (s, 3H, 23-H), 0.82 (s, 3H, 24-H),
0.80–0.74 (m, 1H, 5-H) ppm; 13C-NMR (126 MHz, CDCl3):
δ = 176.4 (C-28), 171.1 (Ac), 151.0 (C-20),
109.5 (C-29), 81.1 (C-3), 72.8 (C-33), 70.1 (C-32), 55.9 (C-17), 55.6 (C-5), 50.7 (C-9), 50.2 (C-18), 47.0 (C-19),
42.6 (C-14), 41.8 (C-34), 40.9 (C-8), 39.1 (C-31), 38.6 (C-1), 38.5 (C-22), 37.9 (C-4), 37.9 (C-13), 37.3 (C-10),
34.5 (C-7), 33.9 (C-16), 31.0 (C-21), 29.5 (C-15), 28.1 (C-23), 25.7 (C-12), 23.9 (C-2), 21.4 (Ac), 21.1 (C-11),
19.6 (C-30), 18.4 (C-6), 16.6 (C-24), 16.3 (C-25), 16.3 (C-26), 14.8 (C-27) ppm; MS (ESI, MeOH): m/z = 585
(100 %, [M + H]+), 607 (47 %, [M + Na]+); analysis calcd for C36H60N2O4 (584.89): C 73.93, H 10.34, N
4.79; found: C 73.69, H 10.54, N 4.56.
(3β)-N-(2-Aminoethyl)-3-hydroxy-lup-20(29)-en-28-amide (24). Compound 24 was prepared from 17
according to general procedure C.◦Column chromatography (SiO2, CHCl3/MeOH 9:1) gave 24 (yield:
◦
86%); m.p. 218–220 C; [
α
]
D = +4.5 (c 0.300, DMSO); Rf = 0.28 (CHCl3/MeOH 9:1);IR (KBr):
ν
= 3424br
s, 2941m, 1636m, 1449m, 1044m, 879w cm−1; 1H-NMR (400 MHz, DMSO-d6):
δ = 7.53 (t, J = 5.5 Hz, 1H,
NH), 4.67–4.63 (m, 1H, 29-Ha), 4.54–4.51 (m, 1H, 29-Hb), 3.15–2.92 (m, 4H, 32-Ha, 19-H, 32-Hb, 3-H),
2.60–2.51 (m, 3H, 13-H, 31-Ha, 31-Hb), 2.16–2.09 (m, 1H, 16-Ha), 1.82–1.65 (m, 2H, 22-Ha, 21-Ha), 1.62 (s,
3H, 30-H), 1.61–0.92 (m, 17H, 12-Ha, 1-Ha, 2-Ha, 2-Hb, 6-Ha, 18-H, 16-Hb, 11-Ha, 22-Hb, 15-Ha, 6-Hb,
7-Ha, 7-Hb, 21-Hb, 9-H, 11-Hb, 15-Hb), 0.92–0.78 (m, 2H, 12-Hb, 1-Hb), 0.91 (s, 3H, 27-H), 0.87 (s, 3H,
23-H), 0.84 (s, 3H, 26-H), 0.76 (s, 3H, 25-H), 0.65 (s, 3H, 24-H), 0.64–0.60 (m, 1H, 5-H) ppm; 13C-NMR
(101 MHz, DMSO-d6):
δ = 175.6 (C-28), 150.9 (C-20), 109.1 (C-29), 76.8 (C-3), 54.9 (C-5), 54.9 (C-17), 50.1
(C-9), 49.7 (C-18), 46.2 (C-19), 41.9 (C-14), 41.8 (C-32), 41.4 (C-31), 40.3 (C-8), 38.5 (C-4), 38.3 (C-1), 37.7
(C-22), 36.7 (C-10), 36.6 (C-13), 34.0 (C-7), 32.4 (C-16), 30.3 (C-21), 28.9 (C-15), 28.1 (C-23), 27.1 (C-2),
25.2 (C-12), 20.6 (C-11), 19.0 (C-30), 17.9 (C-6), 15.9 (C-25), 15.8 (C-26), 15.7 (C-24), 14.3 (C-27) ppm; MS
(ESI, MeOH): m/z = 499 (100 %, [M + H]+); analysis calcd for C32H54N2O2 (498.80): C 77.06, H 10.91, N
5.62; found: C 76.81, H 11.07, N 5.55.
(3β)-N-[2-(Dimethylamino)ethyl]-3-hydroxy-lup-20(29)-en-28-amide (25). Compound 25 was prepared from
18 according to general procedure C. Column chromatography (SiO2, CHCl3/MeOH 95:5) gave 25
(yield: 89%); m.p. 118–120 ◦C; [
ν
α
]D =
−
4.4◦ (c 0.330, MeOH); Rf = 0.43 (CHCl3/MeOH 9:1); IR (KBr):
= 3408br s, 2944s, 2866s, 1638s, 1528m, 1464s, 1376m, 1246m, 1194m, 1044m, 880m cm−1; H-NMR
1
(500 MHz, CDCl3): δ = 6.26 (t, J = 4.9 Hz, 1H, NH), 4.73–4.71 (m, 1H, 29-Ha), 4.58–4.56 (m, 1H, 29-Hb),
3.37–3.22 (m, 2H, 31-H), 3.16 (dd, J = 11.0, 5.2 Hz, 1H, 3-H), 3.10 (ddd, J = 11.1, 11.1, 4.2 Hz, 1H, 19-H),
2.46–2.37 (m, 3H, 13-H, 32-H), 2.22 (s, 6H, 33-H, 330-H), 2.06–1.89 (m, 2H, 16-Ha, 21-Ha), 1.79–1.72 (m,
1H, 22-Ha), 1.67 (s, 3H, 30-H), 1.72– 1.16 (m, 16H, 12-Ha, 1-Ha, 2-Ha, 2-Hb, 18-H, 6-Ha, 16-Hb, 15-Ha,
11-Ha, 22-Hb, 6-Hb, 7-Ha, 7-Hb, 21-Hb, 9-H, 11-Hb), 1.15–1.10 (m, 1H, 15-Hb), 1.04–0.96 (m, 1H, 12-Hb),
0.95 (s, 3H, 27-H), 0.95 (s, 3H, 23-H), 0.93 (s, 3H, 26-H), 0.91–0.81 (m, 1H, 1-Hb), 0.80 (s, 3H, 25-H), 0.74
(s, 3H, 24-H), 0.69–0.64 (m, 1H, 5-H) ppm; 13C-NMR (126 MHz, CDCl3):
δ = 176.4 (C-28), 151.2 (C-20),
109.4 (C-29), 79.1 (C-3), 58.3 (C-32), 55.9 (C-17), 55.5 (C-5), 50.8 (C-9), 50.2 (C-18), 47.0 (C-19), 45.3 (C-33,
C-330), 42.6 (C-14), 40.9 (C-8), 39.0 (C-4), 38.9 (C-1), 38.6 (C-22), 38.0 (C-13), 37.4 (C-10), 36.7 (C-31), 34.6
(C-7), 33.8 (C-16), 31.1 (C-21), 29.6 (C-15), 28.1 (C-23), 27.6 (C-2), 25.8 (C-12), 21.1 (C-11), 19.6 (C-30), 18.5
(C-6), 16.3 (C-26), 16.2 (C-25), 15.5 (C-24), 14.8 (C-27) ppm; MS (ESI, MeOH): m/z = 527 (100%, [M +
H]+); analysis calcd for C34H58N2O2 (526.85): C 77.51, H 11.10, N 5.32; found: C 77.40, H 11.22, N 5.18.

Molecules 2018, 23, 2558
16 of 19
(3
β)-N-(2-Pyrrolidin-1-ylethyl)-3-hydroxy-lup-20(29)-en-28-amide (26). Compound 26 was prepared from
19 according to general procedure C. Column chromatography (SiO2, CHCl3/MeOH 95:5) gave 26
◦
◦
14.7 (c 0.320, MeOH); Rf = 0.40 (CHCl3/MeOH 9:1);
(yield: 80%); m.p. 253–256 C (decomp.); [
α
]
D
=
−
IR (KBr):
ν
= 3426br s, 2942s, 2866s, 2696m, 2620m, 2500m, 1638s, 1544m, 1450m, 1376m, 1246w, 1196w,
1046m, 880m cm−1; H-NMR (500 MHz, CDCl3):
δ = 7.54 (t, J = 5.7 Hz, 1H, NH), 4.73–4.71 (m, 1H,
1
29-Ha), 4.59–4.57 (m, 1H, 29-Hb), 3.91–3.79 (m, 2H, 33-Ha, 330-Ha), 3.78–3.61 (m, 2H, 31-H), 3.24–3.15
(m, 3H, 32-H, 3-H), 3.07 (ddd, J = 10.9, 10.9, 4.2 Hz, 1H, 19-H), 2.89–2.78 (m, 2H, 33-Hb, 330-Hb), 2.42
(ddd, J = 12.6, 12.6, 3.6 Hz, 1H, 13-H), 2.31–2.18 (m, 3H, 16-Ha, 34-Ha, 340-Ha), 2.15–2.05 (m, 2H, 34-Hb,
340-Hb), 1.96–1.78 (m, 2H, 22-Ha, 21-Ha), 1.67 (s, 3H, 30-H), 1.73–1.14 (m, 17H, 12-Ha, 1-Ha, 2-Ha, 2-Hb,
18-H, 16-Hb, 6-Ha, 22-Hb, 11-Ha, 6-Hb, 21-Hb, 7-Ha, 7-Hb, 15-Ha, 9-H, 11-Hb, 15-Hb), 1.01–0.92 (m, 1H,
12-Hb), 0.96 (s, 6H, 23-H, 27-H), 0.91 (s, 3H, 26-H), 0.89–0.81 (m, 1H, 1-Hb), 0.81 (s, 3H, 25-H), 0.75 (s,
3H, 24-H), 0.70–0.65 (m, 1H, 5-H) ppm; 13C-NMR (126 MHz, CDCl3): δ0= 177.9 (C-28), 151.1 (C-20),
109.5 (C-29), 79.1 (C-3), 56.6 (C-32), 56.1 (C-17), 55.5 (C-5), 54.8 (C-33, C-33 ), 50.8 (C-9), 50.4 (C-18), 47.0
(C-19), 42.6 (C-14), 40.9 (C-8), 39.0 (C-4), 38.9 (C-1), 38.2 (C-22), 37.9 (C-13), 37.4 (C-10), 35.7 (C-31),
0
34.6 (C-7), 33.2 (C-16), 31.1 (C-21), 29.7 (C-15), 28.1 (C-23), 27.6 (C-2), 25.8 (C-12), 23.5 (C34, C-34 ), 21.1
(C-11), 19.6 (C-30), 18.5 (C-6), 16.4 (C-26), 16.3 (C-25), 15.5 (C-24), 14.8 (C-27) ppm; MS (ESI, MeOH):
m/z = 553 (100%, [M + H]+); analysis calcd for C36H60N2O2 (552.89): C 78.21, H 10.94, N 5.07; found:
C 78.00, H 11-09, N 4.81.
(3β)-N-(2-Piperidin-1-ylethyl)-3-hydroxy-lup-20(29)-en-28-amide (27). Compound 27 was prepared from
20 according to general pr◦ocedure C. Column chromatography (SiO2, CHCl3/MeOH 95:5) gave 27
◦
(yield: 83%); m.p. 141–144 C (decomp.); [
α
]
= +4.9 (c 0.315, CHCl3); R = 0.21 (CHCl3/MeOH 95:5);
D
f
IR (KBr):
ν
= 3424br s, 2940s, 2866m, 2364w, 1638s, 1508m, 1452m, 1376m, 1248w, 1194w, 1128w, 1046m
= 6.78–6.57 (m, 1H, NH), 4.76–4.69 (m, 1H, 29-Ha), 4.61–4.56 (m,
cm−1; 1H-NMR (400 MHz, CDCl3):
δ
1H, 29-Hb), 3.48–3.31 (m, 2H, 31-H), 3.17 (dd, J = 11.1, 5.0 Hz, 1H, 3-H), 3.08 (ddd, J = 11.0, 10.8, 3.9 Hz,
1H, 19-H), 2.65–2.46 (m, 6H, 32-H, 33-H, 330-H), 2.37 (ddd, J = 12.4, 12.3, 3.6 Hz, 1H, 13-H), 2.15–2.08
(m, 1H, 16-Ha), 2.00–1.88 (m, 1H, 21-Ha), 1.85–1.76 (m, 1H, 22-Ha), 1.68 (s, 3H, 30-H), 1.73–1.08 (m,
23H, 12-Ha, 35-H, 1-Ha, 18-H, 34-H, 340-H, 6-Ha, 2-Ha, 2-Hb, 16-Hb, 15-Ha, 11-Ha, 22-Hb, 21-Hb, 6-Hb,
7-Ha, 7-Hb, 9-H, 11-Hb, 15-Hb), 1.08–0.95 (m, 1H, 12-Hb), 0.96 (s, 3H, 27-H), 0.95 (s, 3H, 23-H), 0.91 (s,
3H, 26-H), 0.91–0.82 (m, 1H, 1-Hb), 0.80 (s, 3H, 25-H), 0.74 (s, 3H, 24-H), 0.70–0.63 (m, 1H, 5-H) ppm;
13C-NMR (101 MHz, CDCl3):
δ
= 176.6 (C-28), 151.1 (C-20), 109.5 (C-29), 79.1 (C-3), 57.3 (C-32), 56.1
0
(C-17), 55.5 (C-5), 54.3 (C-33, C-33 ), 50.7 (C-9), 50.1 (C-18), 47.1 (C-19), 42.7 (C-14), 40.9 (C-8), 39.0 (C-4),
38.9 (C-1), 38.4 (C-22), 38.1 (C-13), 37.4 (C-10), 35.5 (C-31), 34.6 (C-7), 33.6 (C-16), 31.1 (C-21), 29.6 (C-15),
0
28.1 (C-23), 27.6 (C-34, C-34 ), 25.8 (C-12), 25.5 (C-35), 24.0 (C-2), 21.1 (C-11), 19.6 (C-30), 18.5 (C-6), 16.3
(C-26), 16.2 (C-25), 15.5 (C-24), 14.8 (C-27) ppm; MS (ESI, MeOH): m/z = 567 (100%, [M + H]+); analysis
calcd for C37H62N2O2 (566.92): C 78.39, H 11.02, N 4.94; found: C 78.16, H 11.20, N 4.71.
(3
β)-N-(2-Piperazin-1-ylethyl)-3-hydroxy-lup-20(29)-en-28-amide (28). Compound 28 was prepared from
21 according to general procedure C. Column chromatography (SiO2, CHCl3/MeOH/NH4OH
◦
90:10:0.5) gave 28 (yield: 90%); m.p. 146–148 C (decomp.); [
0.30 (CHCl3/MeOH/NH4OH 90:10:1); IR (KBr): = 3422br s, 3072w, 2942s, 2868m, 1638s, 1510m,
1452m, 1376m, 1320w, 1248w, 1194w, 1138w, 1046w, 754m cm−1; 1H-NMR (400 MHz, CDCl3):
= 6.19
α]
= +6.5◦ (c 0.380, CHCl3); Rf =
D
ν
δ
(t, J = 4.9 Hz, 1H, NH), 4.77–4.70 (m, 1H, 29-Ha), 4.63–4.55 (m, 1H, 29-Hb), 3.42–3.28 (m, 2H, 31-H), 3.17
(dd, J = 11.1, 5.0 Hz, 1H, 3-H), 3.09 (ddd, J = 10.8, 10.3, 3.7 Hz, 1H, 19-H), 2.97 (t, J = 4.9 Hz, 4H, 34-H,
340-H), 2.58–2.42 (m, 6H, 32-H, 33-H, 330-H), 2.37 (ddd, J = 12.4, 12.3, 3.7 Hz, 1H, 13-H), 2.06–1.89 (m,
2H, 16-Ha, 21-Ha), 1.68 (s, 3H, 30-H), 1.81–1.08 (m, 18H, 22-Ha, 12-Ha, 1-Ha, 18-H, 2-Ha, 2-Hb, 6-Ha,
16-Hb, 15-Ha, 11-Ha, 22-Hb, 6-Hb, 21-Hb, 7-Ha, 7-Hb, 9-H, 11-Hb, 15-Hb), 1.07–0.95 (m, 1H, 12-Hb), 0.97
(s, 3H, 27-H), 0.95 (s, 3H, 23-H), 0.92 (s, 3H, 26-H), 0.96–0.83 (m, 1H, 1-Hb), 0.80 (s, 3H, 25-H), 0.75 (s,
3H, 24-H), 0.70–0.64 (m, 1H, 5-H) ppm; 13C-NMR (101 MHz, CDCl3):
δ = 176.3 (C-28), 151.0 (C-20),
109.6 (C-29), 79.1 (C-3), 57.1 (C-32), 56.0 (C-17), 55.5 (C-5), 53.6 (C-33, C-330), 50.7 (C-9), 50.1 (C-18),
47.2 (C-19), 46.0 (C-34, C-340), 42.7 (C-14), 40.9 (C-8), 39.0 (C-4), 38.9 (C-1), 38.5 (C-22), 38.1 (C-13), 37.4

Molecules 2018, 23, 2558
17 of 19
(C-10), 35.6 (C-31), 34.6 (C-7), 33.9 (C-16), 31.1 (C-21), 29.6 (C-15), 28.2 (C-23), 27.6 (C-2), 25.8 (C-12), 21.1
(C-11), 19.6 (C-30), 18.5 (C-6), 16.4 (C-26), 16.3 (C-25), 15.5 (C-24), 14.8 (C-27) ppm; MS (ESI, MeOH):
m/z = 568 (100%, [M + H]+); analysis calcd for C36H61N3O2 (567.90): C 76.14, H 10.83, N 7.40; found:
C 75.96, H 11.01, N 7.27.
(3
according to general procedure C. Column chromatography (SiO2, CHCl3/MeOH 9:1) gave 29 (yield:
85%); m.p. 130–133 ◦C; [ = +4.8◦ (c 0.380, DMSO); R = 0.31 (CHCl3/MeOH 88:12);IR (KBr):
3448br s, 2941s, 2867m, 1636m, 1534m, 1452m, 1384w, 1195w, 1045w cm−1; 1H-NMR (400 MHz, DMSO-d6):
= 7.55 (t, J = 5.8 Hz, 1H, NH), 4.67–4.62 (m, 1H, 29-Ha), 4.55–4.50 (m, 1H, 29-Hb), 3.12–2.88 (m, 4H,
β)-N-(4-Aminobutyl)-3-hydroxy-lup-20(29)-en-28-amide (29). Compound 29 was prepared from 22
α]
D
ν =
f
δ
31-Ha, 19-H, 3-H, 31-Hb), 2.61–2.51 (m, 3H, 13-H, 32-Ha, 32-Hb), 2.18–2.09 (m, 1H, 16-Ha), 1.81–1.64
(m, 2H, 22-Ha, 21-Ha), 1.62 (s, 3H, 30-H), 1.61–1.51 (m, 2H, 1-Ha, 12-Ha), 1.49–0.98 (m, 19H, 2-Ha, 2-Hb,
6-Ha, 18-H, 34-Ha, 34-Hb, 11-Ha, 16-Hb, 15a, 22-Hb, 6-Hb, 33-Ha, 33-Hb, 7-Ha, 7-Hb, 9-H, 21-Hb, 11-Hb,
15-Hb), 0.97–0.78 (m, 2H, 1-Hb, 12-Hb), 0.90 (s, 3H, 27-H), 0.86 (s, 3H, 23-H), 0.84 (s, 3H, 26-H), 0.76 (s,
3H, 25-H), 0.65 (s, 3H, 24-H), 0.64–0.59 (m, 1H, 5-H) ppm; 13C-NMR (101 MHz, DMSO-d6):
δ = 175.2
(C-28), 150.9 (C-20), 109.1 (C-29), 76.8 (C-3), 55.0 (C-5), 54.8 (C-17), 50.1 (C-9), 49.7 (C-18), 46.1 (C-19),
41.9 (C-14), 41.2 (C-32), 40.3 (C-8), 38.5 (C-4), 38.3 (C-31), 38.2 (C-1), 37.7 (C-22), 36.7 (C-10), 36.6 (C-13),
34.0 (C-7), 32.4 (C-16), 30.4 (C-21, C33), 28.9 (C-15), 28.1 (C-23), 27.2 (C-2), 26.7 (C-34), 25.2 (C-12), 20.6
(C-11), 19.0 (C-30), 18.0 (C-6), 16.0 (C-25), 15.8 (C-26), 15.7 (C-24), 14.3 (C-27) ppm; MS (ESI, MeOH):
m/z = 527 (100 %, [M + H]+), 1053 (22 %, [2M + H]+); analysis calcd for C34H58N2O2 (526.45): C 77.51,
H 11.10, N 5.32; found: C 77.38, H 11.30, N 5.13.
(3
from 23 according to general procedure C. Column chromatography (SiO2, CHCl3/MeOH 9:1) gave
30 (yield: 91%); m.p. 182–183 ◦C; [ 1.1◦ (c 0.315, MeOH); Rf = 0.45 (CHCl3/MeOH/NH4OH
]D =
β)-N-[2-(2-Aminoethoxy)ethyl]-3-hydroxy-lup-20(29)-en-28-amide (30). Compound 30 was prepared
α
−
90:10:1); IR (KBr):
ν
= 3424br s, 2942s, 2868m, 1636s, 1534m, 1450w, 1384w, 1318w, 1278w, 1248w, 1196w,
1108m, 1044m cm−1; H-NMR (500 MHz, CD3OD):
δ = 4.72–4.68 (m, 1H, 29-Ha), 4.61–4.57 (m, 1H,
1
29-Hb), 3.70–3.63 (m, 2H, 33-H), 3.57–3.51 (m, 2H, 32-H), 3.47–3.31 (m, 2H, 31-H), 3.15–3.05 (m, 4H,
3-H, 19-H, 34-H), 2.56 (ddd, J = 12.8, 12.4, 3.6 Hz, 1H, 13-H), 2.12 (ddd, J = 13.1, 3.3, 3.2 Hz, 1H, 16-Ha),
1.93–1.78 (m, 2H, 21-Ha, 22-Ha), 1.69 (s, 3H, 30-H), 1.76–1.63 (m, 2H, 12-Ha, 1-Ha), 1.65–1.10 (m, 15H,
2-Ha, 2-Hb, 18-H, 16-Hb, 6-Ha, 15-Ha, 22-Hb, 11-Ha, 6-Hb, 7-Ha, 7-Hb, 21-Hb, 9-H, 11-Hb, 15-Hb),
1.09–0.96 (m, 1H, 12-Hb), 1.00 (s, 3H, 27-H), 0.97 (s, 3H, 26-H), 0.95 (s, 3H, 23-H), 0.95–0.88 (m, 1H, 1-Hb),
0.86 (s, 3H, 25-H), 0.75 (s, 3H, 24-H), 0.73–0.69 (m, 1H, 5-H) ppm; 13C-NMR (126 MHz, CD3OD):
δ =
179.6 (C-28), 152.3 (C-20), 110.0 (C-29), 79.6 (C-3), 71.4 (C-32), 67.8 (C-33), 57.1 (C-17), 56.9 (C-5), 52.1
(C-9), 51.4 (C-18), 48.2 (C-19), 43.5 (C-14), 42.0 (C-8), 40.7 (C-34), 40.1 (C-1), 39.9 (C-4), 39.7 (C-31), 39.3
(C-22), 39.0 (C-13), 38.3 (C-10), 35.6 (C-7), 34.1 (C-16), 31.9 (C-21), 30.6 (C-15), 28.6 (C-23), 28.0 (C-2),
27.0 (C-12), 22.2 (C-11), 19.6 (C-30), 19.5 (C-6), 16.9 (C-24), 16.8 (C-25), 16.1 (C-26), 15.1 (C-27) ppm; MS
(ESI, MeOH): m/z = 543 (100 %, [M + H]+), 1085 (10 %, [2M + H]+); analysis calcd for C34H58N2O3
(542.58): C 75.23, H 10.77, N 5.16; found: C 75.11, H 10.94, N 4.97.
5. Conclusions
A set of 28 ursolic and betulinic carboxamides was prepared and screened for their cytotoxic
activity using SRB assays. This screening revealed the compounds derived from betulinic acid to
be more potent than those from ursolic acid. In particular, betulinic carboxamides 24
remarkable cytotoxicity, as indicated by EC50 values lower than 1 M. The most potent compounds of
this study are (3 )-N-[2-(dimethylamino)ethyl]-3-hydroxy-lup-20(29)-en-28-amide (25, EC50 = 0.2
0.01 M for A2780 tumor cells; SI = 1.50) and (3 )-N-(2-pyrrolidin-1-ylethyl)-3-hydroxy-lup-20(29)-
en-28-amide (26, EC50 = 0.2 0.05 M for MCF-7 tumor cells; SI = 2.00). Compound 18 showed
the highest selectivity for HT29 tumor cells (EC50 = 0.3 0.02 M; SI = 3.33). Further structural
–30 showed
µ
β
µM
±
µ
β
µM
±
µ
±
µ
modifications showed that the replacement of the 3-O-acetyl moiety has an impact on the cytotoxicity
and on the selectivity, respectively. Compounds 25 and 26 were selected for extended biological testing

Molecules 2018, 23, 2558
18 of 19
employing MCF-7 and A2780 human tumor cell lines. Fluorescence microscopic images revealed both
of the compounds to show characteristics of apoptosis.
Supplementary Materials: Supplementary data related to this article can be found at http://www.mdpi.com/
1420-3049/23/10/2558/s1.
Author Contributions: M.K. and R.C. conceived and designed the experiments; M.K. performed the experiments;
L.F. performed the biological assays and experiments; M.K., L.F., A.A.-H. and R.C. analyzed the data and wrote
the paper.
Funding: We acknowledge the financial support of the Open Access Publications Fund of the Martin-Luther-
University Halle-Wittenberg.
Acknowledgments: We’d like to thank R. Kluge for measuring the ESI-MS spectra and Dieter Ströhl and his
team for the NMR spectra. Thanks are also due to Jana Wiese and Vivienne Simon for measuring the IR spectra
and optical rotations. The cell lines were kindly provided by Thomas Müller (Dept. of Haematology/Oncology,
Martin-Luther University Halle-Wittenberg).
Conflicts of Interest: The authors declare no conflict of interest.
References
1.
Heymach, J.; Krilov, L.; Alberg, A.; Baxter, N.; Chang, S.M.; Corcoran, R.B.; Dale, W.; DeMichele, A.;
Diefenbach, C.S.M.; Dreicer, R.; et al. Clinical cancer advances 2018: Annual report on progress against
cancer from the american society of clinical oncology. J. Clin. Oncol. 2018, 36, 1020–1044. [CrossRef]
[PubMed]
2.
3.
4.
5.
6.
7.
Laszczyk, M.N. Pentacyclic triterpenes of the lupane, oleanane and ursane group as tools in cancer therapy.
Planta Medica 2009, 75, 1549–1560. [CrossRef] [PubMed]
Chen, H.; Gao, Y.; Wang, A.; Zhou, X.; Zheng, Y.; Zhou, J. Evolution in medicinal chemistry of ursolic acid
derivatives as anticancer agents. Eur. J. Med. Chem. 2015, 92, 648–655. [CrossRef] [PubMed]
Csuk, R. Betulinic acid and its derivatives: A patent review (2008–2013). Expert Opin. Ther. Pat. 2014, 24,
913–923. [CrossRef] [PubMed]
Tripathi, L.; Kumar, P.; Singh, R. A review on extraction, synthesis and anticancer activity of betulinic acid.
Curr. Bioact. Compd. 2009, 5, 160–168. [CrossRef]
Csuk, R.; Schwarz, S.; Siewert, B.; Kluge, R.; Ströhl, D. Synthesis and antitumor activity of ring a modified
glycyrrhetinic acid derivatives. Eur. J. Med. Chem. 2011, 46, 5356–5369. [CrossRef] [PubMed]
Heller, L.; Sommerwerk, S.; Tzschöckell, F.; Wiemann, J.; Schwarz, S.; Siewert, B.; Al-Harrasi, A.; Csuk, R.
First occurrence of a furano-glycyrrhetinoate and its cytotoxicity. Arch. Pharm. 2015, 348, 889–896. [CrossRef]
[PubMed]
8.
9.
Ma, C.-M.; Wu, X.-H.; Hattori, M.; Wang, X.-J.; Kano, Y. Hcv protease inhibitory, cytotoxic and apoptosis-
inducing effects of oleanolic acid derivatives. J. Pharm. Pharm. Sci. 2009, 12, 243–248. [CrossRef] [PubMed]
Ma, C.-M.; Cai, S.-Q.; Cui, J.-R.; Wang, R.-Q.; Tu, P.-F.; Hattori, M.; Daneshtalab, M. The cytotoxic activity of
ursolic acid derivatives. Eur. J. Med. Chem. 2005, 40, 582–589. [CrossRef] [PubMed]
10. Kahnt, M.; Heller, L.; Grabandt, P.; Al-Harrasi, A.; Csuk, R. Platanic acid: A new scaffold for the synthesis of
cytotoxic agents. Eur. J. Med. Chem. 2018, 143, 259–265. [CrossRef] [PubMed]
11. Kahnt, M.; Heller, L.; Al-Harrasi, A.; Schäfer, R.; Kluge, R.; Wagner, C.; Otgonbayar, C.; Csuk, R. Platanic
acid-derived methyl 20-amino-30-norlupan-28-oates are potent cytotoxic agents acting by apoptosis.
Med. Chem. Res. 2018, 27, 1757–1769. [CrossRef]
12. Heller, L.; Knorrscheidt, A.; Flemming, F.; Wiemann, J.; Sommerwerk, S.; Pavel, I.Z.; Al-Harrasi, A.; Csuk, R.
Synthesis and proapoptotic activity of oleanolic acid derived amides. Bioorg. Chem. 2016, 68, 137–151.
[CrossRef] [PubMed]
13. Skehan, P.; Storeng, R.; Scudiero, D.; Monks, A.; McMahon, J.; Vistica, D.; Warren, J.T.; Bokesch, H.; Kenney, S.;
Boyd, M.R. New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst. 1990, 82,
1107–1112. [CrossRef] [PubMed]
14. Swiss Institute of Bioinformatics—SwissAMDE. Available online: www.swissadme.ch (accessed on 21
September 2018).
15. Deng, S.L.; Baglin, I.; Nour, M.; Cavé, C. Synthesis of phosphonodipeptide conjugates of ursolic acid and
their homologs. Heteroat. Chem. 2008, 19, 55–65. [CrossRef]

Molecules 2018, 23, 2558
19 of 19
16. Petrenko, N.; Elantseva, N.; Petukhova, V.; Shakirov, M.; Shul’ts, E.; Tolstikov, G. Synthesis of betulonic acid
derivatives containing amino-acid fragments. Chem. Nat. Compd. 2002, 38, 331–339. [CrossRef]
17. Bai, K.-K.; Yu, Z.; Chen, F.-L.; Li, F.; Li, W.-Y.; Guo, Y.-H. Synthesis and evaluation of ursolic acid derivatives
as potent cytotoxic agents. Bioorg. Med. Chem. Lett. 2012, 22, 2488–2493. [CrossRef] [PubMed]
18. Yang, X.; Li, Y.; Jiang, W.; Ou, M.; Chen, Y.; Xu, Y.; Wu, Q.; Zheng, Q.; Wu, F.; Wang, L. Synthesis and
biological evaluation of novel ursolic acid derivatives as potential anticancer prodrugs. Chem. Biol. Drug Des.
2015, 86, 1397–1404. [CrossRef] [PubMed]
Sample Availability: Samples of all compounds are available from the authors.
©
2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).